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Abstract: 
 
Background: 
Diabetes mellitus is one of the major risk factors for cardiovascular disease and 
associated mortality. There is increasing recognition of the need to assess glucose 
tolerance in all patients with cardiovascular disease but less agreement about the 
most appropriate screening methodology in all patient groups. Until recently the 
diagnosis of diabetes mellitus was based on WHO 1998 criteria. However an 
International Expert Committee (IEC) comprising experts from ADA, W.H.O and 
I.D.F came together and recommended the use of an HbA1c cut-off of 6.5% for the 
diagnosis of diabetes mellitus. Recently we developed and published a simple T2DM 
Screening Algorithm (T2DSA) based on the FPG and HbA1c. 
Aims: 
Our aims were  
1. To determine the prevalence of undiagnosed diabetes and impaired glycaemic 
state (IGS) and compare the WHO 1998 and IEC criteria for diagnosis of T2DM in 
patients admitted to hospital with acute coronary syndrome  
2. To investigate the role of screening algorithm that includes fasting plasma glucose 
(<7.0 mmol/l) and HbA1c (>6.0%) to accurately define glucose tolerance in patients 
admitted with an acute coronary syndrome (ACS)  
3. To explore the potential of a panel of biomarkers to enhance the predictive power 
of our screening tests. 
Hypothesis: 
In patients with acute coronary syndrome, long term glycaemic status can be 
determined on hospital admission using reproducible and easily obtainable 
measures other than the oral glucose tolerance test. 
Methods: 
A prospective 3 year study carried out in two large inner city hospitals in United 
Kingdom. The participants were all admitted to hospital with ACS and underwent 
an initial OGTT within 7 days of hospital admission which was followed up by 
glycaemic stratification at 3 months. 
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Results: 
Patients (n=118) were included in the analysis. The prevalence of diabetes mellitus 
was 20% and 16% respectively according to the W.H.O and IEC criteria at baseline. 
The prevalence of diabetes remained similar at 3 months at 21%. However two 
thirds of participants with IGS and a third of those with DM changed their glycaemic 
status at 3 months. This could be possibly due to stress hyperglycaemia as urinary 
cortisol creatinine ratio was elevated in patients who had T2DM at baseline 
compared to NGT and IGS. 
The two diagnostic criteria appeared to identify different cohort of patients. Our 
screening algorithm had sensitivity of over 85% at baseline in comparison with 
W.H.O 1998 criteria. We also designed a diabetes predictor score based on age, 
fasting plasma glucose and HbA1c and it had an excellent sensitivity of over 80% 
and negative predictive value of over 90%. These novel formulae have a clear 
advantage over IEC criteria with better sensitivity. 
At baseline mean C-peptide, glucagon, intact pro-insulin and HOMA IR were higher 
in the diabetic group compared to normal and IGS groups. HOMA IS was lower in 
the diabetic and IGS groups compared to normal cohort  At 3 months mean C-
peptide, IL 1 RA, TIMP 2 and intact pro-insulin were higher in the diabetic group 
compared to NGT and IGS groups.  
Conclusion: 
The W.H.O and IEC diagnostic criteria identify different populations with diabetes 
at baseline as well as 3 months. This is clinically relevant as we are basing screening 
in a high risk population on these criteria. The IEC criteria do not identify patients 
with IGS which is known to be associated with increased cardiovascular morbidity 
and mortality. Our screening algorithm can reduce the number of OGTTs and detect 
half of the participants with IGS; however it cannot be used on its own to detect 
diabetes mellitus. A Diabetes Predictor Score demonstrated potential to diagnose 
diabetes and has an excellent sensitivity, specificity and negative predictive value. 
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1.1 Diabetes Mellitus: 
 
Type 2 diabetes mellitus (T2DM) is an extremely common lifelong health condition. 
The latest figures from Diabetes U.K suggest 2.9 million people are known to suffer 
from diabetes in U.K while another 850,000 remain undiagnosed. By 2025 there will 
be more than 4 million people with diabetes in the U.K. In England the current 
prevalence of diabetes is estimated at around 5.5% (1). 
 T2DM is a global epidemic with an estimated worldwide prevalence of 6.4% (285 
million) in 2010 that is forecast to rise to 7.7% (438 million) in 2030 (2). In addition 
344 million people have impaired glucose tolerance (IGT) that is forecast to increase 
to 472 million by 2030 (2).  
The World Health Organisation (WHO) defines diabetes mellitus (DM) as: “a 
metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both. The effects of DM include long-
term damage, dysfunction and failure of various organs such as retinopathy with 
potential blindness, nephropathy that may lead to renal failure, and/or neuropathy 
with risk of foot ulcers, amputation, Charcot joints, and features of autonomic 
dysfunction, including sexual dysfunction. People with diabetes are at increased risk 
of cardiovascular, peripheral vascular and cerebrovascular disease.”   
The health, economic and social burden of T2DM is immense. The U.K. spends 10% 
of total NHS spending on treating diabetes and its complications (3). World wide it 
amounts for 12% of the total health budget (1). At the same time the rising 
prevalence of obesity presents a massive challenge to the world wide health services. 
T2DM is a complex disorder. Genetic and environmental factors play a major part in 
the pathogenesis of T2DM (Fig 1) (4).  Mechanistically it is related to insulin 
resistance (IR) and beta cell dysfunction. Obesity leads to development of IR and 
impaired glucose tolerance (IGT) (4-6). IGT may progresses to T2DM. There are 
several pathways leading to the development of IR including hormonal imbalance 
(e.g. increased leptin, reduced adiponectin and elevated glucagon) and increased 
cytokines (e.g. tumour necrosis factor-α, interleukin-6) (4,6,7-10). Impaired glycaemic 
state (IGS) progresses to T2DM when the amount of insulin released cannot 
overcome IR. The decline in pancreatic beta cell function is related to damage caused 
by chronic hyperglycaemia (glucotoxicity), oxidative stress (OS) and inflammation 
(11-14). Some of these will be covered in more detail in the upcoming chapters. 
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1-1: Pathogenesis of Type 2 Diabetes Mellitus (Adapted with permission from 15) 
 
1.2 Acute Coronary Syndrome: 
 
The term acute coronary syndrome (ACS) includes a wide spectrum of 
cardiovascular diseases ranging from unstable angina (UA) and non-ST segment 
elevation myocardial infarction (NSTEMI) to ST segment elevation myocardial 
infarction (STEMI) (16, 17).  3 million people are admitted with a STEMI and 4 
million with NSTEMI worldwide (17, 18).  
Short term mortality is higher among patients admitted with STEMI as compared to 
long term which is higher with NSTEMI (17, 19). The main distinction among these 
conditions is based on the underlying severity of the disease and the resulting 
myocardial damage. UA and NSTEMI is associated with partially occlusive while 
STEMI with stable occlusive thrombus (16) Fig 1.2.  
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1-2: Spectrums of Acute Coronary Syndromes (Adapted with permission from 16) 
 
Inflammation plays a major part in the pathogenesis of atherosclerosis. Any insult to 
the endothelium e.g. hyperglycaemia, dyslipidaemia, smoking, hypertension or 
obesity can lead to adhesion of monocytes to the arterial lumen (20, 21). Monocytes 
become macrophages and ingest modified lipoproteins to transform into foam cells. 
The core of the plaque consists of foam cells, modified lipoproteins, apoptotic debris, 
collagen and von-Willebrand factor (20, 22). Plaque formation starts from childhood 
however clinical manifestations of ACS happen when they become large enough to 
cause circulatory blockage (20, 23, and 24). 
Plaques can become symptomatic in three ways (20, 25). Firstly endothelial 
disruption causes exposure of collagen and von Willebrand factors that lead to 
thrombus formation (20, 26). Secondly angiogenesis (new vessel formation) is 
promoted by factors within the plaque (20, 27).Upon rupture production of thrombin 
leads to release of platelet derived growth factor (PDGF) and transforming growth 
factor beta (TGF beta) which stimulate smooth muscle production (20, 28). Thirdly 
fibrous cap of plaques can be weakened by mediators like interferon gamma which 
inhibit collagen production (20, 22). In addition existing collagen is also left 
weakened which leads to micro tear in the fibrous plaque (20, 29). Plaque disruption 
leads to contact between blood and collagen which leads to platelet activation (20, 
30). This in turn leads to transformation of glycoprotein IIb/IIIa receptors on 
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platelets (20, 31). Fibrinogen connects to these leading to platelet aggregation. 
Factors such as plasminogen activator inhibitor (PAI) that inhibit fibrinolysis 
promote clot formation. These are raised in conditions like type 2 diabetes mellitus 
(20, 32). 
 
 
1-3 Pathophysiology of atherosclerosis (Adapted with permission from 16) 
Medical management includes bed rest, oxygen, morphine and the use of 
antithrombotic (aspirin, clopidogrel, low molecular weight heparin, warfarin and 
glycoprotein IIb/IIIa inhibitors) and anti-angina (nitrates and beta and calcium 
channel blockers) medications.  More recent studies demonstrated that an early 
interventional therapy (percutaneous angioplasty or coronary artery bypass 
grafting) provide a clear benefit over conservative management (16). Definitive 
management is always based on risk stratification (20). 
1.3 Diabetes Mellitus and Acute Coronary Syndrome: 
 
T2DM is associated with an increased risk of cardiovascular disease (CVD) and 
mortality (33). Despite advances in the management of CVD and risk factors we 
have only achieved limited success in terms of reduction in mortality when 
compared to patients without diabetes (33, 34). Some of the excess risk is related to 
already established risk factors like obesity, hypertension and dyslipidaemia (33, 35). 
However these factors do not fully explain the increased risk (33, 36). Therefore it 
has been suggested that there are additional factors some of which may be the 
following (33) (Table 1). 
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1-1 Traditional and Non-traditional risk factors for CVD in diabetes (Adapted 
with permission from 33) 
 
Pathogenesis of CVD in diabetes is related to a complex interaction between many of 
these factors as they rarely exist in isolation. These include factors such as insulin 
resistance (IR) and inflammation (33, 37). Inflammation, endothelial and clotting 
abnormalities are all associated with IR and may play a role in the pathogenesis of 
diabetes as well as CVD (33, 38).The following figure is an illustration of some of the 
interaction between the non-traditional risk factors of CVD in diabetes mellitus (33). 
I will discuss some of these factors in more detail next as they form an important 
part of our project. 
 
1-4: Interaction between non-traditional risk factors of CVD. (Adapted with 
permission from 33) 
 
18 
 
1.3.1 Insulin Resistance: 
 
Insulin resistance syndrome or metabolic syndrome was first described as 
association between obesity, T2DM, IR, high triglycerides (TG) and low high density 
lipoprotein (HDL) cholesterol (33, 39 and 40). More recently it has been shown to be 
associated with inflammation, CVD, endothelial and clotting abnormalities (33, 41) 
as well as obstructive sleep apnoea, non-alcoholic fatty liver disease and polycystic 
ovary syndrome. Traditionally research studies have identified insulin sensitivity, 
plasma insulin levels or formulas based on plasma insulin and glucose (homeostatic 
model assessment or popularly known as HOMA) to define insulin resistance (33). 
All of these do however have their limitations. Whatever method is used there is a 
clear association between insulin resistance and the incidence of ischaemic heart 
disease as well as all cause cardiovascular mortality (33). 
Obesity is one of the major associations of IR. Central deposition of fat appears to 
have a close relationship with DM, IR and high blood pressure (33, 42). Adipose 
tissue also produces a number of biomarkers which are responsible for some of the 
consequences of IR as well as being predictors of CVD. Some of these include C-
reactive protein (CRP), Interleukin 6(IL-6) and tumour necrosis factor alpha (TNF@). 
Patients with IRS have been shown to have high levels of CRP in the circulation (33, 
43). TNF@ expression is increased in obesity. It inhibits lipoprotein lipase and 
endothelial nitric oxide synthase (NOS) and promotes adhesion of monocytes as well 
as having effects at insulin receptor level. IL-6 is similarly shown to effect endothelial 
function (33).  
The term “diabetic dyslipidaemia” refers to high TGs and/or low HDL-cholesterol 
and is suggestive of IR (33, 44 and 45). Hormone sensitive lipase activity is increased 
and there is also higher breakdown of stored TGs (33, 46). The levels of low density 
lipoprotein cholesterol (LDL-cholesterol) may be similar between subjects with and 
without IR (33, 45). 
Hypertension is another association of IR. Obese people with IR are known to have 
higher blood pressure (33). Even slight reduction in weight is associated with lower 
fasting plasma insulin levels and a reduction in blood pressure (33, 47). The 
mechanisms responsible for this association are multifactorial as is the underlying 
complex disorder of hypertension (33, 48). 
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1.3.2 Endothelial Dysfunction: 
 
Endothelial dysfunction plays a major role in the pathogenesis of CVD in diabetes 
(33, 49). Nitric oxide and prostacyclin have vasodilator properties and are protective 
to the endothelium. These actions are opposed by vasoconstrictor substances like 
endothelin 1. Biochemical markers of endothelial dysfunction include von 
Willebrand factor (vWF), thrombomodulin and adhesion molecules (33, 50).  
Endothelial dysfunction starts early in life and progresses with the passage of time 
(33, 51-53). At a cellular level insulin induces NOS which regulates nitric oxide 
synthesis (33, 54). Abnormalities of insulin signalling through the 
phosphatidylinositol-3 kinase pathway also accounts for some of the higher risk (33, 
55-57). Both these features lead to abnormalities of nitric oxide which acts as 
protector of the endothelium (33). 
Asymmetric dimethylarginine (ADMA) is an inhibitor of NOS and its levels are 
directly related to abnormalities of the insulin mediated glucose mechanism in IR. 
Therefore elevated levels of ADMA may also explain some of the elevated risk of 
CVD in diabetes (33, 58 and 59). Other features such as reduced activity of the 
enzyme that produces tetrahydrobiopterin(BP4) and higher expression of adhesion 
molecules also contribute to risk of IR (33, 60 and 61). 
1.3.3 Impaired fibrinolysis and prothrombotic state: 
 
The fibrinolytic system is maintained by a balance between factors which promote 
and inhibit plasminogen. These include tissue type plasminogen activator and 
plasminogen activator inhibitor type 1 (PAI-1) (33, 62). This balance is disturbed in 
diabetes and IR and is another explanation for the higher incidence of CVD in 
diabetics as well as non-diabetics (33, 63-67). Studies have shown an increased 
activity of PAI-1 in IR states like obesity and polycystic ovary syndrome (33, 68 and 
69).  
Platelet aggregation and the number of glycoprotein receptors are increased in 
diabetes. A number of other non-specific abnormalities of coagulation are also 
suggested in diabetes and can partly explain the increased risk for CVD in diabetes 
(33, 70 and 71). 
The production and release of PAI-1 is controlled by insulin as well as its precursors 
and other biomarkers (33, 72). Levels of PAI-1 are clearly shown to have a positive 
correlation with metabolic (IR) syndrome (33, 72). PAI-1 levels are increased in 
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atherosclerotic plaques with T2DM (33, 73). A combination of actions of insulin on 
PAI-1 and the clotting cascade can also partly explain the elevated risk of CVD (33). 
1.3.4 Inflammation: 
 
Following is a schematic representation of the interaction between inflammation, 
circulatory factors released by adipose tissue and CVD in diabetes. 
 
 
 
1-5: Interplay between inflammation, I.R and atherosclerosis (Adapted with 
permission from 33) 
Inflammation has been shown to play a part in the pathogenesis of both CVD and 
T2DM (33).  Factors such as infectious agents, adipokines and oxidized lipids 
promote the release of IL-6 which in turn leads to the release of CRP from the liver 
(33, 74). 
Elevated levels of CRP have been shown in the setting of obesity as well as other 
features of metabolic syndrome (33, 75). Thus inflammation plays an important and 
complex role in pathogenesis of both T2DM and CVD. 
21 
 
 
 
1.4 Screening for Diabetes Mellitus and Impaired Glycaemic 
Status in Acute Coronary Syndrome: 
 
There is increasing recognition of the need to assess glucose tolerance in all patients 
admitted to a coronary care unit (CCU) with acute coronary syndrome (ACS). 
Studies have shown an association between abnormal glycaemic status and long 
term mortality and morbidity in such groups as well as immediate outcome (76-81, 
94). It is also quite clear that people admitted to hospital with ACS have a higher 
incidence of impaired glycaemic status (IGS) and T2DM (81-85, 94). Evidence also 
clearly supports that early detection of diabetes plays an important role in 
preventing complications (86-88). In addition lifestyle measures and/or metformin 
(outside license) therapy may be useful in those with IGS (89).  
Despite all of this, most centres in the UK have not implemented a screening strategy 
in these patients, which partly reflects the lack of consensus on a screening modality 
(i.e. fasting plasma glucose, HbA1c and oral glucose tolerance test).  
The European Association for the study of Diabetes (EASD) recommends the use of 
an oral glucose tolerance test to investigate glycaemic abnormalities in patients with 
CVD but without a known diagnosis of diabetes mellitus (90, 94). To the contrary the 
American Heart Association Diabetes Committee of the Council on Nutrition, 
Physical Activity and Metabolism does not support the use of OGTT (91, 94).  This is 
partly due to the absence of conclusive evidence supporting early intensive 
glycaemic control improves cardiovascular outcome. It is also unclear whether high 
blood glucose is a cause or effect and whether it should be treated or just taken as a 
marker due to stress (92, 93). 
A survey carried out in Holland suggests 76% of cardiologists do not check HbA1c 
in patients with ACS before discharge. Therefore, it is unlikely that a more 
impractical test like OGTT would be used more often than HbA1c (93, 95).  
The rapid transit of patients through coronary care units makes it very difficult to 
arrange an investigation like OGTT which needs logistical support and prior 
organization to arrange fasting the night before as well as the appropriate glucose 
drink etc. being available at the right time. In addition patients are usually being 
discharged within 3 days locally so asking them to fast on one of those days when 
they are also having a therapeutic procedure like angioplasty can be difficult. 
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Reports have suggested OGTT at the time of discharge in patients with ACS is 
reliable in predicting glycaemic status at 3 and 12 months (81).  However, closer 
examination of these data suggest that less than 50% of patients diagnosed with 
diabetes at discharge have T2DM on OGTT at 12 months (81). More recently people 
have been looking at comparison of the different diagnostic criteria in this cohort 
(93).  
1.5 Diagnostic Criteria for Diabetes Mellitus: 
 
Until recently diagnosis of diabetes mellitus was based on WHO 1998 criteria. 
Patients with venous FPG>7.0 mmol/l were classified with diabetes mellitus, if 6.1 to 
6.9 mmol/l with impaired fasting glycaemia (IFG) and <6.0 mmol/l with normal 
fasting glucose. Patients with a 2 hour plasma glucose (2hPG) >7.8 and <11.1 mmol/l 
obtained from venous blood were classified as having impaired glucose tolerance 
(IGT) and those with 2 hour plasma glucose >11.1 mmol/l with DM (96). 
Representatives of European Association for Study of Diabetes (EASD), American 
Diabetes Association (ADA) and International Diabetes Federation (IDF) came 
together in 2009 and in a consensus statement recommended the use of an HbA1c 
cut-off of 6.5% as a diagnostic marker for diabetes mellitus provided the method 
used for testing HbA1c is standardized and subjected to quality assurance protocols 
(97).More recently World Health Organization (WHO) has also adopted it in the 
following statement 
“HbA1c can be used as a diagnostic test for diabetes providing that stringent 
quality assurance tests are in place and assays are standardised to criteria aligned 
to the international reference values, and there are no conditions present which 
preclude its accurate measurement. An HbA1c of 6.5% is recommended as the cut 
point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes 
diagnosed using glucose tests.” (98) 
This has led to some debate in the field of diabetes and biochemistry. On the one 
hand HbA1c provides a clear advantage over OGTT. OGTT is expensive, time 
consuming unpleasant and unsuitable for large scale screening (97). Added to the 
poor reproducibility, because of the high coefficient of variation of the 2 hour value, 
alternative screening methods like FPG and HbA1c were needed.  By contrast 
HbA1c testing can be costly, needs to be standardized and may not be readily 
available in some areas of the world (97). In addition HbA1c can be dependent on 
race/ethnicity (97, 99 and 100). It will also be inaccurate with certain anaemia’s and 
hemoglobinopathies. There is no validation for HbA1c testing in children and only 
partial correlation between average glucose levels and HbA1c.  
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HbA1c testing may also not be suitable in other conditions such as pregnancy, recent 
blood loss and recent blood transfusions (97).My aim was to explore the role of 
alternative screening methods which are more reproducible, easier to perform, less 
expensive and suitable for large scale screening in our cohort of patients admitted to 
hospital with acute coronary syndrome.   
The Diabetes team at Selly Oak Hospital, Birmingham developed and published a 
T2DM screening algorithm based on the FPG and HbA1c.  (101). This algorithm was 
derived from oral glucose tolerance test (OGTT) capillary samples in 500 consecutive 
UK patients referred with IFG according to  World Health Organization criteria. It 
was validated in 500 UK patients as well as venous specimens in 1175 unselected 
Australian patients (101). In the derivation cohort median age was 61 years (50-69) 
with 52% male and 12% South Asian. Median HbA1c was 6.2% (5.8-6.6%) and FPG 
6.7 mmol/l (6.3-7.2 mmol/l). The FPG identified 36% of patients with diabetes 
mellitus while OGTT identified a further 12%. The derived algorithm, (HbA1c 
greater than or equal to 6.0% with FPG < 7.0 mmol/l) was utilized to identify 
patients requiring an OGTT to diagnose diabetes. When applied to the UK validation 
cohort, sensitivity was 97% and specificity 100%. The algorithm was equally effective 
in the unselected group, aged 59 years (49-68 years) with sensitivity 93% and 
specificity 100%. HbA1c was 6.0% (5.6-6.6%) and FPG 6.0 mmol/l (5.3-6.8 mmol/l), 
with 26% having IFG. Use of the algorithm would have reduced the number of 
OGTTs performed in the UK validation cohort by 33% and in the Australian cohort 
by 66%. This suggested that use of this algorithm could simplify procedures for 
diagnosis of diabetes and could also be used for monitoring pre-diabetes. Validation 
was still needed in other populations and other patient groups (101). 
 
1-6: Algorithm combining HbA1c and FPG (Adapted with permission from 101) 
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My aim was to look at the role of this algorithm in reducing the need to perform an 
OGTT in this cohort. In addition we decided to consider comparing the two 
diagnostic criteria (WHO 1998 and Expert Committee 2009). 
1.6 Dysglycaemia and Cardiovascular disease and mortality: 
                         
It has been shown that diabetic patients who have never had myocardial infarction 
have a risk similar to non-diabetic patients who have had a prior myocardial 
infarction. Therefore it is suggested that all patients with diabetes should be 
considered to have the same risk as if they have already had a myocardial infarct 
(102). 
In the previous section I have shown the diagnostic criteria for IFG and IGT 
according to WHO diagnostic criteria. Both these groups are high risk of developing 
T2DM as well as increased risk of cardiovascular disease (103). The progression of 
IGT to T2DM typically varies from 1.5 to 4% annually (104). Both IFG and IGT are 
supposed to be intermediary disorders of carbohydrate metabolism (103). The 
worldwide prevalence of IGT is much higher compared to IFG. It has been 
suggested that this may be due to age, sex and ethnicity (103,105). Similarly IGT is 
also suggested to lead to a higher risk of cardiovascular disease as compared to IFG 
(103). Some of the factors associated with increased risk of dysglycaemia include 
raised body mass index, advancing age, family history of diabetes, selected 
ethnicities, history of IGT or gestational diabetes mellitus, and lipid abnormalities 
[106-110]. Although many were shown to be associated with T2DM, most of them 
were also shown to be associated with IGT in an analysis of data from the Second 
National Health and Nutrition Examination Survey (NHANES II).(111) 
The Honolulu heart programme examined over 8000 participants over 23 years and 
showed a clear association of higher incidence of total mortality cardiovascular 
disease and mortality with dysglycaemia (112). The Funagata diabetes study in 1999 
examined over 2500 citizens of Funagata over 7 years and showed significantly 
reduced survival from cardiovascular disease and stroke among those with IGT and 
T2DM (113).In this study the IFG group were not shown to have reduced survival 
from stroke or cardiovascular mortality compared to those with IGT (113). The 
Framingham offspring study also showed similar findings and suggested the 
examining of 2 hour glucose levels is important as an independent risk factor for 
cardiovascular disease (114). In a combined analysis of 6 prospective studies body 
mass index (BMI), fasting and 2 hour glucose concentrations were the two 
parameters shown to be the best independent predictors of progression to T2DM 
(115). 
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In a meta-analysis of 15 studies dysglycaemia was clearly shown to be associated 
with increased cardiovascular mortality. Patients with glucose concentrations more 
than or equal to 6.1-8.0 mmol/l without previously known T2DM had a 3.9-fold 
higher risk of dying than patients without diabetes who had lower glucose 
concentrations. Glucose concentrations higher than 8.0-10.0 mmol/l on admission 
were associated with increased risk of congestive heart failure or cardiogenic shock 
in patients without diabetes (77). Another study has demonstrated that each 18 
mg/dl (1 mmol/l) rise in blood glucose in patients admitted to hospital with ACS 
appears to lead to a 4 fold rise in mortality (116). 
In a separate study by Hofsten et al, the impact of dysglycaemia was studied on 
cardiovascular outcome. The investigators went on to correlate the glucose levels 
with echocardiographic markers of both systolic and diastolic dysfunction. They 
were able to show a linear relationship between dysglycaemia and indices of systolic 
and diastolic function. Similarities were shown in the relationship between pro-B 
type natriuretic peptide and glycaemic abnormalities. A clear association was shown 
in this study between the glycaemic abnormalities and cardiovascular outcomes as 
well as readmission. The impact on cardiovascular outcome remained even after 
correcting for the echocardiographic abnormalities. The follow-up duration in this 
study varied from 12 to 44 months (117). 
Earlier in the section I mentioned the W.H.O definition of IFG and IGT i.e. the 
groups which are supposed to be at increased risk of developing T2DM and in the 
case of IGT also at elevated risk of cardiovascular disease and mortality (96). The 
American Diabetes Association have also examined this and issued separate 
guidelines. In addition to 6.5% as the diagnostic cut-off for diabetes, the ADA 
recommends the use of an HbA1c value of 5.7-6.4% (39-46 mmol/mol) to identify 
patients with an increased risk of future diabetes (118). However studies which have 
looked at comparing these two groups using W.H.O and ADA diagnostic criteria in 
the setting of acute admissions from cardiac disease, have shown clear differences in 
the populations detected by these two guidelines (93). 
Other studies have also looked at therapeutic intervention in people with IGT to 
prevent or delay progression to T2DM. One such programme examined lifestyle-
intervention and administration of metformin to see if it would prevent or delay the 
development of diabetes (89). The life style intervention reduced the incidence by 
58% while metformin reduced it by 31% as compared to non-intervention group. The 
average numbers needed to treat was 6.9 in the life style intervention and 13.9 in the 
metformin group (89). 
I examined the incidence of IFG as well as IGT in this acute setting in our patient 
group. We also went on to analyse the comparison of those with IGS according to 
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W.H.O and ADA criteria in our population group. A unique feature of my work was 
that this comparison was carried out at baseline as well as follow-up at 3 months. 
1.7 Stress Hyperglycaemia: 
 
Stress hyperglycaemia represents an increased blood glucose level as a result of 
activation of neurohormonal processes when exposed to stress (119). Increased 
glucose during stress is result of sympathetic nervous system activation and raised 
production of catecholamines (adrenaline and noradrenaline) and cortisol that 
stimulate processes of gluconeogenesis, glycogenolysis and lipolysis. These 
hormones are responsible for insulin resistance, at the receptor and post receptor 
level (120-122). In addition other hormones like glucagon and growth hormone are 
also considered part of the counter regulatory response to stress. However it has not 
been clearly established whether the role of growth hormone is cause or effect. 
Recent studies have shown a high incidence of glycaemic abnormalities in patients 
being admitted to hospital with ACS (81). Further sub analysis has been carried out 
to look at the reasons behind this abnormality.  
Circulating catecholamine levels did not appear to be directly related to this 
abnormality. However a possible role for them at sympathetic nerve endings has not 
been established (119, 123).  
On the other hand circulating cortisol levels (glucocorticoids) appear to have a 
bigger role to play in the glycaemic regulation (119). 
Insulin levels appear to be increased in the acute setting of ACS (124), hence 
suggesting high incidence of insulin resistance. Insulin increase may be related to the 
high glucose levels which in turn are likely to be caused by cortisol release (119).  
The relationship between insulin levels and the size of the infarct has been explored 
in a number of studies with conflicting findings (119, 123). 
Other studies have however suggested stress hyperglycaemia plays a more 
important role in the pathogenesis of ACS. However there was a difference in the 
timings at which samples were collected and most of the patients did not undergo 
coronary intervention which is now considered the mainstay of management of ACS 
(119, 125). 
I planned to determine the utility of urinary cortisol creatinine ratio as a marker of 
glucocorticoid response to stress in our participants. These were collected within 7 
days of hospital admission and then repeated at the second visit at 3 months. I 
wanted to examine if there was any difference between baseline and 3 month ratios 
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and whether they correlated with the glycaemic stratification. We also studied 
glucagon levels as part of the pancreatic biomarkers. 
1.8 Oxidative Stress: 
 
The term oxidative stress (OS) refers to an imbalance between the production of free 
radicals and the defence mechanisms that prevent cell damage (126). Free radical 
injury has been implicated in the aetiology and progression of many chronic 
diseases, including type 2 diabetes mellitus (127-130).  
Free radical species are a variety of highly reactive molecules that can be divided 
into different reactive oxygen species (ROS), reactive nitrogen species (RNS) and 
reactive chlorine species (RCS). A common feature of cells that are damaged by 
hyperglycaemia is the presence of ROS/RNS causing OS (132,133). 
 
 
1-7: Mechanism of hyperglycaemia related complications. (Adapted with 
permission from 131) 
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Intracellular hyperglycaemia results in an increased synthesis of diacylglycerol 
(DAG), which is a critical activating cofactor, for Protein Kinase C (PKC) (133, 134). 
PKC activation results in a variety of effects on gene expression resulting in 
decreased production of endothelial nitric oxide synthase (eNOS), increased 
endothelin-1, increased TGF- β, Vascular endothelial Growth Factor (VEGF) and 
increased plasminogen activator inhibitor-1 (Figure 1-8) (133). These changes are 
associated with vascular occlusion and increased endothelial permeability resulting 
in tissue damage. 
 
 
1-8: Consequences of activation of PKC by hyperglycaemia. (Adapted with 
permission from 133) 
 
It is now being recognized that oxidative stress (OS) is the main mechanism for 
hyperglycaemia induced micro and macro vascular complications in diabetes. 
Furthermore oxidative stress leads to complications even in patients with metabolic 
syndrome without diabetes. However the role of oxidative stress in predicting 
glycaemic status in patients with macro vascular disease i.e. ACS has not been 
examined before. 
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1.9 Matrix Metalloproteinases (MMPs): 
 
These belong to a group of zinc binding proteolytic enzymes which have been 
proposed as playing a major part in the pathogenesis of atherosclerosis. Several 
conditions like T2DM, CVD and rheumatoid arthritis are associated with an 
increased activity of MMPs (135,136). MMPs 2 and 9 are two of the common species 
in the myocardium as well as the vasculature (135, 137). MMP 9 plays a major role in 
the vasculature and myocardium remodelling (135, 138). The unstable areas of the 
atherosclerotic plaques have been shown to have higher expression of MMP 9 (135, 
139). Its levels as well as those of MMP 2 are also raised in the circulation in acute 
coronary syndromes (135, 140). There is still considerable debate about the interplay 
between MMPs and their inhibitors (tissue inhibitor of matrix metalloproteinase’s or 
TIMP) and their role in diabetic vascular disease. TIMP 2 is the main inhibitor of 
MMP-2 (135).  
Diabetes is associated with a high incidence of mortality from CVD. It has been 
postulated that part of this could be related to abnormalities in the synthesis and 
function of MMPs (135, 141). Low activity of MMPs has been associated with 
diabetic nephropathy (135, 142 and 143). Some studies have shown elevated and 
others lower levels of MMPs 2 and 9 in diabetic subjects. Others have shown no 
difference as well (135, 144-147). Some of the postulation suggests it could be related 
to the use of different medications as well as coronary intervention (135, 148-150).  
Chronic hyperglycaemia has been shown as associated with reduced levels of MMP 
9 in circulation (135). The effects of acute elevations in glucose appear a little more 
complicated. Studies have shown no change in MMP 9 at 90 minutes following an 
OGTT (147) but a reduction at 120 minutes (135). On the other hand no change was 
reported in MMP 2 (135). 
I decided to look at the activity of MMP-9 in our participants to compare among 
those with normal, impaired glucose tolerance and T2DM. In addition to MMP-9 we 
also measured TIMP 1 and TIMP 2 levels at baseline to examine if it had any link 
with the glycaemic stratification at baseline and again at follow-up. 
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1.10 Vitamin D: 
 
Deficiency of vitamin D is associated with a number of medical conditions including 
T2DM (151). A recent meta-analysis looked at the effects of high vitamin D levels. 
The risk of diabetes mellitus was reduced by 55%, cardiovascular disease by 33% 
and metabolic syndrome by 51% (151, 152). Vitamin D has been shown to play an 
important part in the pathogenesis of T2DM. It is proposed that some of these effects 
are via vitamin D actions on insulin sensitivity and beta cells of pancreas (151, 153-
155). 
 
1-9: Role of Vitamin D in the pathogenesis of insulin resistance (Adapted from 
156).Solid and bold arrows indicate cause and effect relationships; dotted ones 
indicate not firmly established evidence 
Vitamin D has been shown to exert its effects by improving the expression of insulin 
receptors and therefore improving insulin glucose sensitivity (156, 157). Vitamin D 
can also play direct and indirect effects on the beta cells of the pancreas (156, 158). 
Vitamin D receptors are expressed on macrophages, thus suggesting Vitamin D can 
also act on the cytokines and mediate the inflammatory response that plays a major 
role in the pathogenesis of IR and T2DM (151, 159) . 
I decided to examine vitamin D status in our cohort to look for an association of 
vitamin D levels in the circulation and glycaemic status as well as the kind of cardiac 
event. 
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1.11 Serum Fructosamine and HbA1c Standardization: 
 
Blood glucose binds to serum protein by glycation to produce serum fructosamine. 
Its levels in serum are therefore directly related to the degree of glycaemic control. 
Serum fructosamine as a marker has been used clinically as a monitoring tool to help 
patients with diabetes control their blood sugar (160).  
Half-life of albumin (14-20 days) and other proteins (2-23 days) compares rather 
unfavourably with haemoglobin (60 days). Therefore fructosamine will only reflect 
glycaemic control over 2 to 3 weeks as opposed to HbA1c of 6-8 week period (160).  
It is however quite a useful marker in situations where the HbA1c cannot be reliably 
measured. For example the HbA1C test will not be accurate when a patient has a 
condition that affects the average age of red blood cells (RBCs) (i.e. haemolytic 
anaemia or blood loss).  
In these situations checking the full blood count and reticulocyte count can also 
provide quite useful information. Similarly the presence of some haemoglobin 
variants may also affect certain methods for measuring HbA1c (97-99). In these 
cases, fructosamine can be used to monitor glucose control. 
HbA1c was first described as abnormal haemoglobin in diabetics in 1969 (98, 161).  
Later on it was recognized that it is as a result of chemical glycation of N-terminal 
lysine and valines of haemoglobin A (162- 164). A number of small studies 
confirmed the relationship between HbA1c and average glucose and then a larger 
study involving around 643 participants established a validated relationship (98, 
165). 
In view of a possible linear relationship between HbA1c and average blood glucose 
in adults and children it has been suggested that it can be reported as an estimated 
average glucose (98).  
As it is dependent upon red cell turn over it reflects average glycaemic status over 
the preceding 2 to 3 months (98, 164,166). It has long been recognized as the best 
marker for estimating clinical evidence of glycaemic control. However until recently 
there were major issues with regards to different assays which were being used to 
measure HbA1c levels (97, 98, and 164).  
Standardization of HbA1c was first proposed in 1984; however international 
standardization was suggested in the D.C.C.T study in 1993 (88, 98).  
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International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
created a Working group which developed a reference measurement for 
international standardization (98, 167, and 168).  
Closer to home in United Kingdom this process has started and currently a number 
of laboratories are moving towards reporting HbA1c according to IFCC method and 
mmol/mol. Some are currently doing dual reporting in percentage (as shown in 
DCCT) as well as mmol/mol while clinicians working in the field of diabetes get 
used to the new reporting method. 
There were concerns raised about using HbA1c as a diagnostic tool in the past in 
view of the imprecision of some of the assays as well as concerns regarding 
sensitivity. However with the standardization of the assays a lot of these concerns 
have been allayed (98, 164).  
The HbA1c cut-off value recommended for diagnosis is 6.5%. It has been shown to 
have a specificity of 99.6% and sensitivity of 42-44% (164, 169).  
 
1.12Role of novel biomarkers in diagnosing dysglycaemia: 
 
T2DM can affect patients in a number of ways. Similarly all people with T2DM are 
not similar and have different characteristics. While markers such as FPG, OGTT and 
HbA1c can illustrate the glycaemic status of patients they do not completely 
demonstrate the functioning of the pancreas or the way insulin is working 
peripherally (170).   
An obvious target in the pancreas would be to look at the functioning of β cells of 
the pancreas. Studies suggest a 40% reduction in β cell mass in obese patients with 
IFG and 60% in those with T2DM (170-172). 
The pancreas in humans is both an endocrine as well as exocrine organ. 1-2% of the 
pancreas consists of structures called Islet of Langerhans which have at least 5 
different cell types. (α-cells; β-cells; δ-cells; PP cells and ε-cells) The α-cells and β-
cells produce glucagon and insulin respectively which have a dominant role in 
glucose regulation (170). β-cells constitute around 70-80% of the Islets and release 
pro-insulin on exposure to different stimuli such as glucose and amino acids which 
is in turn broken down to release insulin and C-peptide (170, 173).  
It has been almost impossible to discriminate between changes in insulin sensitivity 
and secretion so that there is no explanation at this time for the development and 
progression of T2DM (170, 174).  
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Small changes in insulin can lead to small changes in glucose and vice versa. Fasting 
hyperinsulinaemia is associated with a reduction in β-cell mass and function (170, 
175). 
The following figure demonstrates possible sequence of events in the pathogenesis 
of T2DM. 
 
 
1-10: Characteristics of T2DM development and progression. 
 A) Changes in blood glucose, fasting serum insulin and I.R during initiation and 
progression of T2DM. B) Disposition index showing relationship of insulin 
sensitivity and insulin secretion in β-cells of normal individuals and T2DM. C) Β-
cell loss during disease progression in T2DM. Graph based on findings by Butler 
et al. and Holman et al. [170, 172]. 
1.12.1 C-peptide and Pro-insulin: 
 
Under normal physiological conditions the concentration of pro-insulin is quite low. 
However the pro-insulin concentration is raised in T2DM as it is not properly broken 
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down (176). Therefore pro-insulin can be used as a marker of insulin resistance (177). 
Similarly fasting insulin and C-peptide can be measured to assess β-cell production.  
However as C-peptide has a much longer half-life (20-30 minutes) compared to 
insulin (5 minutes) it is considered a much more accurate marker of insulin 
production (178, 179). Intact pro-insulin is also considered an excellent marker of β-
cell function correlating with insulin resistance and identifying the progression to 
T2DM in clinical practice (180, 181). 
Some studies have also looked at using insulin derived markers to predict long term 
cardiovascular outcomes. One such study examined the role of C-peptide in this 
regard. The study showed C-peptide was superior to other insulin derived measures 
of insulin resistance in predicting cardiovascular and overall death in non-diabetic 
adults. C-peptide predicted cardiovascular death even in subjects with normal 
glucose tolerance and without metabolic syndrome. C-peptide levels were found to 
be a better predictor of cardiovascular and overall mortality compared with serum 
insulin levels as well as other well-known markers of insulin resistance such as 
HOMA-IR, QUICKI, and metabolic syndrome (182). 
1.12.2 Homeostasis model assessment models: 
 
 In addition to the above markers i.e. pro-insulin and C-peptide different 
homeostasis model assessment (HOMA) models are also clinically used to assess β-
cell function/dysfunction (HOMA-β), insulin resistance (HOMA-IR) and insulin 
sensitivity (HOMA-IS) (183). Other markers of insulin resistance such as HOMA-IR 
(using a product of serum insulin and plasma glucose levels) have also been shown 
to be a negative indicator of prognosis for cardiovascular and overall mortality (184). 
Previously Wallander et al demonstrated that patients who had impaired glucose 
tolerance (NGT) at baseline but progressed to develop T2DM had higher 
triglycerides but lower insulin glycaemic index (IGI). The group who had T2DM at 
baseline and remained diabetic had higher triglycerides and HOMA-IR but lower 
IGI (81). 
I decided to utilize some of these in our project and measured intact pro-insulin, C-
peptide, glucagon as well as homeostasis model assessments HOMA- β, HOMA-IR 
and HOMA-IS in our participants.  
1.12.3 Adipokines: 
 
There is evidence from the literature that obesity and more specifically excess 
visceral body fat plays a role in the development of T2DM and metabolic syndrome 
35 
 
as well as risk factors for CVD like dyslipidaemia and insulin resistance (185, 186).  
Adipose tissue produces some markers (adipokines) leptin and adiponectin which 
have been shown as having an association with the risk factors of CVD. Leptin is an 
adipokine which is mainly produced by adipose tissue and is known to play a role in 
regulation of food intake as well as insulin glucose and triglycerides (187). Its levels 
rise in individuals at high risk of CVD. Its levels positively correlate with body fat 
(185). 
Adiponectin is a protein which is only synthesized in adipose tissue. It inhibits the 
production and release of glucose from the liver as well as reducing the levels of free 
fatty acids and oxidation. In addition it has antiatherogenic properties. Its 
concentration in the plasma is inversely proportional to the body weight (185). I 
decided to examine these biomarkers in our participants to examine potential benefit 
in developing a diagnostic model for high risk participants with CVD 
A study of patients with kidney failure demonstrated that patients who suffered 
from new cardiovascular events had lower plasma adiponectin levels than controls 
(188). Following is a graphic illustration of some of the consequences of deficiency of 
adiponectin. 
 
 
1-11 Adiponectin in metabolic syndrome (Adapted from 189) 
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1.12.4 Interleukin-1RA  
 
As illustrated above a number of markers can be used to help to predict incident 
diabetes. Interleukin-1β (IL-1β) is considered one of the most crucial cytokines in the 
development of T2DM as it triggers a cascade of events which in turn result in β cell 
death (190, 191). The harmful effects of this cytokine can be prevented by its 
antagonist IL-1 receptor antagonist (IL-1Ra) which is produced once again by 
adipose tissue and occurs naturally (192).  
This compound had also been used therapeutically and shown to improve glycaemic 
control and β cell function (193). A case control study has also demonstrated 
elevated levels of IL-1Ra being associated with T2DM (194). This could be a sign of 
developing immune and metabolic derangements which happen before 
development of T2DM (195).  
I decided to look at levels of IL-1Ra in our cohort to examine if it could predict the 
onset of developing T2DM in our cohort.  
To summarize this section I looked at measuring a number of novel biomarkers 
which included C-peptide, glucagon, intact pro-insulin, homeostatic assessment 
models, leptin, adiponectin, leptin adiponectin ratio and IL-1Ra in our cohorts. My 
aim was to examine if they aided in developing a mathematical model for T2DM and 
also to see which markers may play a more important role in predicting the onset of 
developing T2DM. 
Rationale of Project: 
 
T2DM is one of the major risk factors for CVD. Patients admitted to hospital with 
ACS have high levels of abnormal glucose homeostasis which has short and long 
term consequences. A number of centres across the UK are now recognising the need 
to assess glucose tolerance in all patients admitted to a coronary care unit (CCU) 
with ACS.  Evidence suggests that only one third of patients have normal glucose 
tolerance and that one third have IGT and further third overt T2DM.  Although we 
are starting to appreciate the magnitude of the problem less is known regarding the 
outcome of patients in these different groups, particularly those with IGT who go 
undiagnosed. 
The overall aim of this study is to characterise glucose tolerance in all patients 
admitted to the Heartlands and Queen Elizabeth Hospitals (QEH) CCU with ACS on 
admission and 3 months after discharge and to evaluates the ability of international 
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criteria and our T2DM screening algorithm to accurately classify the glycaemic 
status. I also evaluated a panel of biomarkers in order to determine whether they 
enhanced the power of our screening tests. 
Hypothesis: 
 
In patients with acute coronary syndrome, long term glycaemic status can be 
determined on hospital admission using reproducible and easily obtainable 
measures other than the oral glucose tolerance test. 
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2. METHODS 
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2.1 Primary Aims: 
 
1. To determine the prevalence of undiagnosed diabetes and impaired 
glycaemic state (IGS) in patients admitted with ACS. 
2. To compare the WHO 1998 and IEC criteria for diagnosis of T2DM in patients 
admitted to hospital with ACS. 
3. To investigate the role of a screening algorithm that includes fasting plasma 
glucose (<7.0 mmol/l) and HbA1c (>6.0%) to accurately define glucose 
tolerance in patients admitted with an acute coronary syndrome (ACS). 
 
2.2 Secondary Aims: 
 
1. To determine whether screening for abnormalities or glucose tolerance are 
similar at the time of admission with ACS and at 3 months post−discharge. 
2. To determine whether glycaemic abnormalities at admission to hospital in 
patients with ACS are secondary to stress hyperglycaemia. 
2.3 Tertiary Aims: 
 
1. To determine whether markers of oxidative stress, pancreatic function and 
inflammation are predictors of glycaemic status in patients with ACS. 
2. To determine long term cardiovascular mortality in patients classified as 
normal glucose tolerance, IGS and undiagnosed type 2 diabetes.  
2.4 Study Design and Settings: 
 
We conducted a prospective study of patients admitted to hospital with ACS. The 
study was carried out at Queen Elizabeth and Heartlands Hospital in Birmingham. 
Patients were identified from ACS and coronary care units (CCU). 
 
The potential participants were identified by visiting CCU and the ACS unit on a 
daily basis. They were approached on the ward and provided with a leaflet about 
the study. Details were verbally explained and the participant offered a chance to 
ask questions. If they agreed to participate in the study they were provided with a 
consent form to sign and recruited in the study. It was made clear that they can 
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withdraw consent at any stage. All patients admitted with ACS were reviewed by 
me or a research nurse (Mrs Susan Maiden) on a daily basis. Patients were given 
adequate time to make their mind and contacted the next day.  
 
The study was approved by the Solihull East and North REC and also by the local 
R&D departments at Queen Elizabeth and Heartlands Hospitals. The study was 
supported by an initial educational grant by the Sanofi-Aventis Excellence in 
Diabetes Programme and further supported by Queen Elizabeth Hospital Charities. 
The funding bodies had no role to play in the design of the study protocol or 
interpretation of the results. 
 
2.5 Study Protocol: 
 
2.5.1 Subjects: 
 
The subjects were patients admitted to Queen Elizabeth and Heartlands Hospital in 
Birmingham with ACS. Patients not known to have diabetes, based upon past 
medical history underwent fasting plasma glucose (FPG), oral glucose tolerance test 
(OGTT) and HbA1c. In addition I also determined serum nitrotyrosine as well as 
vitamin D, rennin and other biomarkers of acute coronary syndrome and insulin 
resistance.  
 
To detect glucocorticoid response to stress we measured spot urinary cortisol 
creatinine ratio. We performed these measurements within 7 days of hospital 
admission on midstream urine early morning sample. 
 
All samples were annonymised and only the study investigators had a code in order 
to be able to link them to individual patients. All participants were asked to return to 
the hospital after 3 months for repeat FPG, OGTT and HbA1c as well as the other 
biomarkers. Urinary cortisol creatinine ratios were repeated at the second visit.  
 
At the follow-up visits, all participants were given healthy dietary and lifestyle 
advice.  The relevant General Practitioners were informed of the results of the 
screening tests after second visit and glycaemic status were defined on basis of 
results of the second OGTT according to WHO 1998 criteria. Patients with venous 
FPG>7.0 mmol/l were classified with diabetes mellitus, if 6.1 to 6.9 mmol/l with 
impaired fasting glycaemia (IFG) and <6.0 mmol/l with normal fasting glucose. 
Patients with a 2 hour plasma glucose (2hPG) >7.8 and <11.1 mmol/l obtained from 
venous blood will be classified as having impaired glucose tolerance (IGT) and those 
with 2 hour plasma glucose >11.1 mmol/l with T2DM. 
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Any participants who were diagnosed as having diabetes mellitus were treated 
according to the local guidelines and followed up in the diabetes clinic. They were 
also offered full support of other staff like dieticians and diabetes specialist nurses. 
2.5.2 Inclusion Criteria: 
 
1. Patients admitted to Queen Elizabeth and Heartlands Hospital coronary care 
with ACS over a 3 year period. The diagnosis of ACS requires the presence of 
chest pain with elevated troponin or ECG changes suggestive of ischemic 
heart disease.  
2. Age 18 to 90 years. 
 
2.5.3 Exclusion Criteria: 
 
1. Patients already known to have T2DM. 
2. Those unable to give informed consent. 
3. Participants under 18 or over 90 years of age. 
4. Participants with normal troponin results and no previous history of ischemic 
heart disease. 
 
2.6 Detailed methodology: 
 
2.6.1 Glucose: 
Venous blood was collected next morning after fasting the previous night and 
fluoride Vacutainers transported to the central laboratory for measurement of 
plasma glucose. Glucose was measured using a hexokinase kit (Cat. No. 
11876899216) and C.f.a.s. calibrator for automated systems (Cat. No. 10759350190) on 
a Roche Modular platform (Roche Diagnostics, E Sussex, UK) with CVs across the 
range of <2%.  
2.6.2 OGTT: 
OGTTs were performed at admission and 3 months. Patients were requested to fast 
the previous evening for 10 hours and bloods collected the next morning. Plasma 
glucose and HbA1c were measured on venous plasma. Glucose was measured using 
the same reagents. For the 75 g OGTT, the patient was asked to drink 113 ml glucose 
polymer drink, Polycal, (Nutricia Clinical Care, Wiltshire, UK) over a period of 5 
min. A further venous blood sample was taken after 2 hours for plasma glucose 
measurement. 
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2.6.3 HbA1c:  
‘DCCT aligned’ HbA1c was reported from an ion exchange, high performance, liquid 
chromatography analyser, TOSOH G7 A1c Variant Mode (Tosoh Bioscience Ltd, 
Worcs, UK) that detects haemoglobin variants.  A reference interval of <6% HbA1c 
was quoted by the manufacturer. HbA1c was not reported in patients with variant 
haemoglobin. 
2.6.4 Vitamin D: 
Vitamin D status was assessed by measuring the concentration of 25 OH vitamin D 
in serum. LC-MS/MS method was used by the local laboratory which has been 
reported as having excellent sensitivity as well as being accurate, precise and quick. 
The principle is based on tandem mass spectrophotometry. 
2.6.5 Nitrotyrosine:  
Modification of tyrosine residues in proteins to 3-nitrotyrosine by peroxynitrite (Fig 
2-1) or other agents has been detected in biological systems that are subject to 
oxidative stress. 3-Nitrotyrosine is formed after a hydrogen ion is removed from 
tyrosine to form tyrosyl. The active tyrosyl then interacts with peroxynitrite to form 
3-nitrotyrosine (196). The efficiency of tyrosine nitration is also dependent on 
biological conditions like local production of reactive species, availability of 
antioxidants and scavengers and accumulation of inflammatory and presence of pro-
inflammatory cytokines (196). It has been implicated in a number of medical 
conditions including T2DM and cardiovascular disease. 
 
2-1: Nitrotyrosine formation 
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The OxiSelect Nitrotyrosine ELISA Kit (catalogue number STA-305) was used for 
detection and quantification of 3-nitrotyrosine in protein sample. The principle was 
based on competitive ELISA. Quantity of 3-nitrotyrosine is determined by 
comparing its absorbance with a known nitrated BSA standard curve. The sensitivity 
range of our assay was 20 nM to 8.0 μM. I followed the instructions issued by the 
manufacturers. The unknown sample or nitrated bovine serum albumin (BSA) 
standards were first added to preabsorbed E1A plate. After brief incubation, anti-
nitrotyrosine antibody was added, followed by horseradish peroxidase (HRP) 
conjugated secondary antibody. The protein nitrotyrosine content was determined 
by comparing with a standard curve prepared from predetermined BSA standards. 
An example of manufacturers curve is shown below: 
 
2-2: Nitrotyrosine ELISA curve provided by the manufacturer 
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An example of curve obtained by me is shown below: 
 
2-3: Nitrotyrosine ELISA standard curve from my plates 
 
2.6.6 Matrix metalloproteinase 9 (MMP-9): 
 
MMP-9 belongs to a series of enzymes called matrix metalloproteinase’s which have 
the ability to breakdown components of the extracellular matrix. MMP-9 has a broad 
range of substrate specificity for a wide variety of native collagens including various 
collagen types as well as gelatin, elastin and proteoglycans (197-199). As explained in 
section 1.9 the activity of MMP-9 is inhibited by tissue inhibitor of matrix 
metalloproteinase’s (TIMP) in a 1:1 molar ratio (197).  
MMP 9 has been implicated in pathogenesis of a number of clinical conditions. 
While it has been implicated in CVD and acute and chronic hyperglycaemia its role 
has not been studied as a positive predictor of glycaemic status in patients with 
CVD. 
The MMP 9 was measured by using the Biotrak MMP-9 ELISA from GE Healthcare.  
The assays principle is based on a two way ELISA sandwich format using two 
antibodies. During first step of the ELISA, MMP-9 present in samples was bound to 
micro plate precoated with the antibody. During the second step, detection antibody 
conjugated with HPO was added forming the immobilized complex. 
Amount of peroxidase bound to each well was determined by the addition of 
tetramethylbenzidine (TMB) ‘ready to use’ substrate. The reaction was stopped by 
addition of acid solution and the resulting colour change measured at 450 nm in a 
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micro plate spectrophotometer. The concentration of MMP-9 was measured by 
interpolation from a standard curve. The following is an example of a standard 
MMP-9 curve obtained by plotting mean optical density (y-axis) against ng/ml 
standard (x-axis). An example of a typical standard curve for the assay is shown. 
 
2-4: Manufacturers standard curve for MMP-9 assay 
 
An example of a curve obtained by me during analysis is shown below: 
 
 
2-5: MMP-9 ELISA curves from my plates 
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2.6.7 Urinary cortisol:  
Measurements of cortisol in urine were carried out by the Roche Modular E170 
cortisol assay which uses Electrochemiluminescence immunoassay (ECLIA). 
2.6.8 Novel Biomarkers: 
 C-peptide and glucagon were measured using commercial MSD assays and 
following manufacturer’s instructions. Intact pro-insulin was measured using an 
Invitron assay. The assays for adiponectin, TIMP1 and TIMP2 used R&D duo-sets 
and were optimised for use on human plasma. The leptin and IL-1Ra assay used 
mouse monoclonal fabs and were again optimised for use on human plasma. 
Following are more details about the assays used: 
The C-peptide kit   MSD Cat  no. was N45CA-1  was optimised for plasma by the 
manufacturer. Assays were carried out according to manufacturer’s instructions. 
 
The leptin and IL-1Ra assays were in-house assays from Mologic and had been 
optimised for use with plasma by performing dilution of linearity and spiked 
sample tests. These test the linear range of the assay within plasma and 
find if there are any issues with the matrix effect with regard to the 
concentration of plasma used. 
Human Glucagon kit       MSD      Cat no. K151HCC-2 
is validated kits for use with serum/ EDTA plasma.  Full details available from MSD 
website.  Assays carried out according to manufacturers' instructions 
 
Intact Proinsulin Luminescence Assay Kit Invitron Cat no.  IV2-002 
http://www.invitron.co.uk/intact-proinsulin-luminescence-assay.html 
is validated kits for use with Heparin and EDTA plasma 
Assays carried out according to manufacturers' instructions. 
 
Human TIMP-1 Duo Set 15 Plates, R&D Systems, Cat no. DY970 
http://www.rndsystems.com/Products/DY970 
Validated in-house using dilutional linearity and spike/recovery assays 
Samples diluted 1:200 in PBS+10% Foetal calf serum assay diluent for testing 
 
Human TIMP-2 DuoSet, 15 Plate, R&D Systems , Cat no. DY971 
http://www.rndsystems.com/Products/DY971 
Validated in-house using dilutional linearity and spike/recovery assays 
Samples diluted 1:200 in 2x R&D assay diluent for testing. 
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Human Adiponectin/Acrp30 DuoSet, 15 Plate, R&D Systems , Cat no. DY1065 
http://www.rndsystems.com/Products/DY1065 
Validated in-house using dilutional linearity and spike/recovery assays 
Samples diluted 1:5000 in 1x R&D assay diluent for testing. 
 
2.7 Data collection: 
 
2.7.1General: 
The following data was collected:  
Age, gender, ethnicity, medications, past medical history, family history, smoking 
history, history of hypertension and dyslipidaemia. 
 2.7.2 Metabolic:  
 The following data was collected: 
 Height, weight, Body Mass index (BMI), HbA1c, OGTT, Lipids, Blood Pressure 
(B.P), and Vitamin D. These were all measured in the respective laboratories. BP was 
measured by an automated device while the patient in sitting position and the left 
arm resting on a table. The 2 measurements were at least 10 minutes apart and the 
first measurement was after about 30 minutes after the start of the consultation. The 
average of the two readings was used in the database. 
 
 2.7.3 Cardiac history: 
The following data was collected:                                   
The nature of the cardiac event, treatment offered and outcome of the underlying 
cardiac condition. 
 
2.7.4 Blood samples:  
These were collected from consenting patients and were used to measure levels of 
nitrotyrosine (as a marker of nitrosative stress) and other biomarkers. Plasma and 
serum samples were collected and stored in a -80 degree Celsius freezer following 
centrifuge. These samples were collected following fasting.                
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2.8 Statistical analysis: 
 
Data analyses were performed using SPSS 15.0 software (SPSS Inc, Chicago, IL). 
Data are presented as mean ± SD or SE or median (interquartile range) or 
frequencies. Independent continuous variables were compared using the 
Student t test or the Mann-Whitney test. Categorical variables were compared using 
the Chi-square test. Correlations between continuous variables were performed 
using the Pearson or Spearman tests. Differences between independent groups were 
assessed by analysis of variance (ANOVA). If the homogeneity of variance 
assumption of ANOVA was violated, the Welch statistics were used to calculate the 
P values. Post-hoc analyses were performed using Games-Howell or Gabriel tests 
depending on whether or not the equal of variance assumption was violated. 
 
To assess the relationship between continuous and/or categorical variables and 
dichotomous outcomes multiple logistic regressions (forced entry method) was used. 
Variables included in the regression models were based on known outcome-related 
risk factors. We assessed multicolinearity in both multiple linear and logistic 
regression models using simple correlations between variables plus the tolerance 
values, and the condition indices. No tolerance values were < 0.1 and no variables 
had strong correlations (r > 0.8). In multiple linear regression models, the residuals 
were examined. In all the models presented, residuals followed a normal 
distribution with uniform variance and there was no relationship between the 
residual and the predictor of interest. Data distribution was assessed using 
histograms and the Shapiro-Wilk test. A P value < 0.05 was considered significant 
unless stated otherwise.  
 
Sample Size: 110 allowing for dropout of 10% 
Justification of Sample Size: 
Based on previous publications (3) we expected a 33% prevalence of T2DM in our 
cohort.  Using our screening algorithm (7) in order to achieve sensitivity of 97% (95% 
confidence interval 84-100%) and specificity of 94% (95% confidence interval 85-98%) 
we needed a sample size of 100 participants. 
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AND IMPAIRED 
GLYCAEMIC STATUS 
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3.1 Clinical Characteristics: 
 
118 participants (age range 31-90, mean 61.3 years) were recruited over a period of 3 
years with a higher number of male participants. While we had representation from 
all ethnicities, we had a majority of white Caucasians recruited in our study. The 
distribution was male and female participants were in keeping with the number of 
admissions to CCU. 
3-1: Sex and ethnicity based distributions of participants 
 Number (%) 
Male 96 81 
Female 22 19 
White Caucasian 94 80 
South Asian 19 16 
Afrocaribbean 5 4 
 
We aimed to recruit patients admitted to coronary care units with both ST segment 
elevation and non ST segment elevation myocardial infarction. This information was 
available for 113 participants.  
3-2: Nature of cardiac events 
 Number (%) 
NSTEMI 64 57 
STEMI 49 43 
 
The following is an illustration of the distribution of some of the baseline parameters 
in our cohort of participants. Mean age was 61.3 (range 31-90) years while mean 
body mass index (BMI) was 28.3 (range 17-47) kg/m². Admission plasma glucose 
was only available for 47 participants (Mean 6.7 mmol/l Range 4.7-12.9 mmol/l) 
thus highlighting deficiencies in comprehensive diabetes screening on admission to 
hospital. 
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3-3: Clinical and metabolic parameters of study participants 
Variables Mean Minimum Maximum +S.D 
Age (Years) 61 31 90 11.9 
BMI (kg/m²) 28 17 47 5.1 
Baseline FPG (mmol/l) 5.7 4.3 13.1 1.2 
Baseline 2hr 
PG(mmol/l) 
8.5 2.4 23.5 3.7 
Baseline HbA1c (%)* 
mmol/mol 
6.1 
43 
4.8 
29 
10.6 
92 
0.84 
Systolic BP (mmHg) 126 91 192 20.5 
Diastolic BP (mmHg) 74 47 115 12 
Admission glucose 
(mmol/l) 
6.7 4.7 12.9 2 
Total cholesterol 
(mmol/l) 
4.4 1.3 8 1.5 
Triglycerides 2.0 0.3 6.7 1.4 
Fructosamine (µmol/l) 213 169 401 28.7 
Vitamin D (nmol/l) 37.6 2.1 119 24.2 
 
* HbA1c was not reported in one participant due to the presence of variant 
Haemoglobin 
Medication history was available for approximately 100 participants. 
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3-4: Drug history at admission 
DRUGS NUMBER OF 
PARTICIPANTS (%) 
Antiplatelet agents (Aspirin and clopidogrel) 93 
Lipid lowering therapy (Statins and 
ezetimibe) 
88 
Beta Blockers 81 
ACE inhibitors/Angiotensin receptor 
antagonists 
87 
Nitrates 10 
Diuretics (Thiazides and K sparing) 19 
Calcium channel blockers 10 
Antiarrhythmic drugs 4 
  
Note: Other miscellaneous agents included agents such as doxazosin, ivadrabine, 
rivoraxaban, finasteride and inhalers. One patient was also on long term 
prednisolone and alendronic acid and was not included in the analysis for urinary 
cortisol creatinine ratio. Most of these drugs were commenced at hospital admission 
apart from antihypertensive and lipid lowering therapy. Data concerning past 
medical history were available on 92 participants. At least a third of the participants 
had no known risk factors for CVD. Smoking appeared to be the most significant 
risk factor in our cohort with at least two thirds of participants giving a history of 
smoking.  
3-5: Past Medical History 
PAST MEDICAL HISTORY YES NO 
Hypertension 32 60 
Smoking (Current and Ex-
smokers) 
62 30 
Dyslipidaemia 29 63 
Ischaemic heart disease 22 70 
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3.2 Classification of Diabetes Mellitus according to W.H.O 1998 
and IEC diagnostic criteria: 
 
On the basis of W.H.O 1998 diagnostic criteria, at baseline 48.3% of participants had 
normal glucose tolerance (NGT) 19.5% T2DM and 32% impaired glycaemic status 
(IGS) which includes patients with IFG 2.5%, IGT 25.4% as well as a combination 
(IFG+IGT) 4.2%.  
8 out of these 23 participants diagnosed with diabetes mellitus were started on 
diabetes treatments based on the original OGTT results due to the severity of their 
glycaemic abnormalities. The remaining 15 underwent a second OGTT and the 
glycaemic status was re-classified. 
3-6: Baseline glycaemic classification 
 Number of participants (%) 
NGT  57 48.3 
IFG 3 2.5 
IGT 30 25.4 
IFG+IGT 5 4.2 
T2DM 23 19.5 
 
Due to the limited number of subjects with IFG alone, for the purpose of some of the 
analyses of the data, the three groups classed as IFG, IGT and IFG+IGT were 
grouped together and called impaired glycaemic status (IGS). This group would be 
considered as high risk for developing T2DM in future.  
3-7: Baseline glycaemic classification for analysis 
 Number of participants (%) 
Normal 57 48.3 
IGS 38 32.1 
T2DM 23 19.5 
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Following is an illustration of ethnicity based glycaemic classification at baseline. 
Although the frequency of patients with T2DM was higher among South Asians 
compared to white Caucasians the trend did not reach statistical significance. 
3-8: Baseline glycaemic classification according to ethnicity 
Ethnicity NGT IGS T2DM 
White Caucasian 45(48%) 31(33%) 18(19%) 
South Asian 9 (47.3%) 5(26.3%) 5(26.3%) 
Afrocaribbean 3(60%) 2(40%) 0 
 
The glycaemic status was reclassified again at 3 months following the initial event. 3 
month data were available for 101 participants (14 drop outs, 3 died). As described 
above 8 participants with DM did not undergo a second OGTT, therefore follow-up 
results for FPG and 2 hour PG were only available for 93 participants. 54% 
participants had NGT, 21% T2DM and 25% IGS with 9% having IFG, 11% IGT and 
5% having a combination of IFG+IGT. The number of participants diagnosed with 
T2DM at 3 months included a combination of those from an initial OGTT who did 
not undergo a second one as well as those whose diagnosis was based on 2nd OGTT 
results. The majority of participants lost to follow-up had NGT at initial OGTT (10 
out of 14). It was noted that the prevalence of IFG nearly tripled at 3 months and at 
least 4 participants who had NGT at hospital discharge had IFG at 3 months. 
The 2 hour plasma glucose was significantly different between baseline and follow-
up with mean value being higher at admission suggesting possible stress 
hyperglycaemia (8.5 vs. 6.8 mmol/l). The possibility was studied in more detail and 
explained in the section on stress hyperglycaemia. 
3-9: Follow-up glycaemic classification 
 Number of participants (%) 
Normal 55 54 
IFG 9 9 
IGT 11 11 
IFG+IGT 5 5 
T2DM 21 21 
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For the purpose of some of the analyses of the data, the three groups classed as IFG, 
IGT and IFG+IGT were grouped together as IGS. This group would be considered as 
high risk for developing T2DM in future. 
3-10: Follow-up glycaemic classification for analysis 
 Number of participants  (%) 
Normal 55 54 
IGS 25 25 
T2DM 21 21 
 
I analysed the glycaemic classification according to ethnicity at 3 months and the 
frequency of T2DM was lower among South Asians compared to White Caucasian 
and also when compared with baseline. However the trend once again did not reach 
statistical significance. 
3-11: Follow-up glycaemic classification according to ethnicity 
Ethnicity NGT IGS T2DM 
White Caucasian 46(58%) 17(21%) 17(21%) 
South Asian 7 (41%) 7(41%) 3(18%) 
Afrocaribbean 2(50%) 1(25%) 1(25%) 
 
The following is an illustration of the incidence of diabetes in our cohort when using 
the IEC criteria as a diagnostic modality. Sections 3.4 and 3.5 offer more detailed 
comparison of the two diagnostic criteria at baseline and follow-up. 
3-12: Classification of glycaemic status at baseline based on IEC diagnostic criteria 
 Number of participants  (%) 
Normal (HbA1c<6.5%) 98 84 
Diabetes (HbA1c >6.5%) 19 16 
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3.3 Relationship of other parameters with glycaemic status: 
                                                                                                                   
My next aim was to explore possible associations of any of the background 
parameters with the glycaemic classification. The main parameters which appeared 
to be positively associated with the glycaemic status at baseline were age, body mass 
index (BMI) and serum fructosamine levels. 
3-13: Associations of means of basic parameters with background glycaemic status 
 NGT IGS T2DM Trend for 
significance 
Age (Years) 57+ 11 64+ 10 67+ 12 0.001 
BMI (kg/m²) 27+4 29+ 4 31+7 0.02 
Fructosamine 207+17 208+ 22 236+47 0.001 
 
The mean age of NGT participants was 57 years. However mean age was higher in 
the IGS and T2DM groups at 64 and 67 years, respectively. This was statistically 
significant with a p value of 0.01 and 0.002 respectively. Mean BMI was 27 kg/m² in 
the normal, 29 kg/m² in the IGS and 31 kg/m² in the diabetic group. Mean BMI was 
higher in the DM group when compared to normal (p=0.02). 
Mean fructosamine was higher in the diabetic group (236) as compared to normal 
and IGS groups (207 and 208 respectively). This was associated with p values 0.004 
and 0.001 respectively.      
The next step was to look at a possible association of any of the clinical parameters 
with the glycaemic classification according to W.H.O 1998 diagnostic criteria at 3 
months. BMI, serum fructosamine were the parameters significantly related to the 
glycaemic classification as illustrated. The association with vitamin D and age was of 
borderline statistical significance only. 
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3-14: Association of means of basic parameters with follow-up glycaemic status 
 NGT IGS T2DM Trend for 
significance 
 Age 59+ 10 61+ 10 66+ 12 0.08 
Vitamin D 43+26 27+16 34+20 0.05 
 BMI (kg/m²) 28+5 28+5 32+5 0.008 
Fructosamine 207+18 213+19 232+49 0.01 
 
The mean BMIs were 28, 28 and 32 kg/m² in the normal, IGS and DM groups. Mean 
fructosamine values were 207, 213 and 232 respectively in the normal IGS and DM 
groups. There was a statistically significant difference between normal and DM 
groups (p=0.01). 
Mean vitamin D levels were 43, 27 and 34 International Units in the normal, IGS and 
DM groups. It was interesting to note that there was a difference between normal 
and IGS groups with the mean vitamin D levels being higher in the normal group 
when compared with the IGS cohort (p=0.05).I also looked at possible association of 
the clinical parameters with glycaemic stratification based on IEC diagnostic criteria. 
The parameters significantly related were age, BMI and serum fructosamine levels 
only. All the three parameters were higher in the diabetic cohort compared to the 
normal group as illustrated in the table below. 
3-15: Association of basic parameters with IEC based glycaemic classification 
 Normal DM Trend 
Mean Age 60+11 67+14 0.05 
Mean BMI 28+5 31+6 0.04 
Mean Fructosamine 209+19 242+50 0.03 
 
In addition I did not see any differences based on sex or ethnicity for baseline or 
follow-up glycaemic classification. 
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3.4 Comparison of W.H.O 1998 and IEC diagnostic criteria: 
 
I decided to compare the W.H.O 1998 diagnostic criteria with the IEC diagnostic 
criteria (HbA1c >=6.5%) at baseline in our study. Currently Diabetes U.K does not 
recommend routine use of HbA1c to diagnose diabetes mellitus in acute hospital 
admissions. 
The two diagnostic criteria were positively related to each other. Figure 3.1 
illustrates our findings. All the participants classified as normal on W.H.O 1998 
diagnostic criteria were all also normal on the IEC diagnostic criteria. However by 
implementing the IEC criteria we would have missed 10 (43%) participants classified 
as T2DM on WHO 1998 diagnostic criteria. As expected the group classified as IGS 
were represented in both groups with 6(16%) of them being classified as having 
T2DM according to the IEC criteria. This does raise the possibility of identifying 
different cohort of patients from the two different diagnostic criteria. 
 
 
 
Figure 3-1: Comparison of outcome of WHO 1998 (x-axis) and IEC diagnostic 
criteria (y-axis) at baseline. 
Another way of illustrating the comparison between the two is shown in the graph 
below. Among participants classified as normal on the IEC diagnostic criteria, 
10(10%) had T2DM on the W.H.O 1998 diagnostic criteria while 31(32%) had IGS and 
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57(58%) NGT. On the contrary among those classified as T2DM on IEC diagnostic 
criteria 6(31.58%) had IGS and 13(68.32%) T2DM on W.H.O 1998 diagnostic criteria. 
 
 
 
Figure 3-2: Comparison of outcome of WHO 1998 (y-axis) and IEC diagnostic 
criteria (x-axis) at baseline 
HbA1c diagnostic criteria and WHO 1998 diagnostic criteria were also positively 
related to each other at 3 months. Closer examination of the graph below however 
shows that the HbA1c criteria would have missed at least 7 (33%) participants who 
had been classified as T2DM on the W.H.O 1998 criteria. However only one 
participant classified as normal on the W.H.O 1998 criteria had T2DM based on IEC 
criteria at 3 months.  
Participants classified as having IGS were mostly normal 22(88%) on the A1C criteria 
with only 3(12%) having T2DM. 
The ADA guidelines do recommend using an HbA1c range of 5.7 to 6.4% to define 
pre-diabetes state. The following table illustrates comparison of individual normal, 
impaired and diabetic groups in the two diagnostic criteria. In all three categories we 
appear to be identifying different cohorts. However the difference appears to be 
most marked in the pre-diabetes group as only a third (35%) of participants 
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classified in this group according to ADA criteria were in the same category 
according to WHO criteria. Indeed over half (54%) of the participants were normal 
according to WHO criteria. 
3-16: Comparison of outcome of ADA and WHO criteria at baseline 
ADA 
criteria 
W.H.O Criteria NGT 
(%) 
W.H.O Criteria IGT 
(%) 
W.H.O Criteria T2DM 
(%) 
Normal 18 14 (78) 3 (17) 1 (5) 
IGS 80 43 (54) 28 (35) 9 (11) 
T2DM 19 0 6 (32) 13 (68) 
 
 
Figure 3-3: Comparison of outcome of WHO 1998(x-axis) and IEC diagnostic 
criteria (y-axis) at 3 months 
Looking at the data in another way at least 7(8.4%) participants classified as normal 
on IEC criteria had T2DM on the OGTT while 22(26.5%) had IGS and 54(65.1%) 
NGT. On the contrary only 1(5%) participant classified as having T2DM on the A1C 
criteria had normal OGTT results. The majority 14(78%) had T2DM on the W.H.O 
criteria, however 3(17%) had IGS. The results for IGS were variable and they were 
represented in both groups (26.5% of normal and 16.67% of T2DM groups on IEC 
criteria). 
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Figure 3-4: Comparison of outcome of WHO 1998 (y-axis) and A1C based (x-axis) 
diagnostic criteria at 3 months. 
The following table illustrates comparison of individual normal, impaired and 
diabetic groups in the two diagnostic criteria at 3 months. In all three categories it is 
obvious that we appear to be identifying different cohorts. However the difference 
appears to be most marked in the pre-diabetes group as less than a third (27%) of 
participants classified in this group according to ADA criteria were in the same 
category according to WHO criteria. Indeed over half (63%) of the participants were 
normal according to WHO criteria. 
3-17: Comparison of outcome of ADA and WHO criteria at 3 months 
ADA 
criteria 
W.H.O Criteria NGT 
(%) 
W.H.O Criteria IGT 
(%) 
W.H.O Criteria T2DM 
(%) 
Normal 16 12 (75) 4 (25) 0 
IGS 67 42 (63) 18 (27) 7 (10) 
T2DM 18 1(5) 3 (17) 14 (78) 
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3.5 Comparison of Screening Algorithm and W.H.O 1998 
diagnostic criteria: 
 
I analysed the utility of our screening algorithm in this acute setting. We should 
specify that this algorithm was originally designed to minimize the number of 
OGTTs in patients referred to hospital biochemistry department with IFG.  
The following figure (3-5) demonstrates a comparison of WHO 1998 diagnostic 
criteria with our screening algorithm. The left hand column represents the group of 
participants with T2DM.  The algorithm had a sensitivity of 87% in detecting them 
and missed only 3 (13%) participants with T2DM. The second column represents the 
group of participants with IGS and by using our screening algorithm we would have 
referred 24 (65%) for an OGTT while missing the remaining 13(35%). The third 
column represents the NGT group and we would have only referred 15(26%) while 
correctly identifying the remaining 42(74%). This has cost saving implications. 
Currently in our two hospitals the cost of an OGTT including laboratory analysis 
and glucose drink etc. comes out as around £62.00. On the other hand the cost of 
testing for HbA1c is only around £9.00 suggesting clear cost savings. 
 
Figure 3-5: Comparison of outcome of WHO 1998 (x-axis) diagnostic criteria with 
screening algorithm (y-axis) at baseline 
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Following (Fig 3-6) is another graphical illustration of the same findings. The first 
column represents group of participants who would have been diagnosed as having 
DM based on elevated FPG. We would have referred the second group for an OGTT 
and it has representation of all the three categories i.e. 15(30.6%) NGT, 24(49%) IGS 
and 10 (20.4%) T2DM. The third column represents patients who would not have 
been referred for OGTT due to our algorithm and we would have missed 3 
participants with DM. The majority of participants in this category belonged to NGT 
42(72%) with 13(22%) having IGS. In total we would have reduced the number of 
OGTTs from 118 to 49 only (58% reduction). 
 
Figure 3-6: Comparison of outcome of WHO 1998 (y-axis) diagnostic criteria and 
screening algorithm (x-axis) at baseline 
One of the primary aims of our project was to look at how our algorithm performed 
with respect to long term glycaemic classification. Our algorithm would have again 
led to a reduction in the number of OGTTs. The left hand column represents the 
group with T2DM and we would have only missed 3 participants (14.3%) with 
T2DM giving a sensitivity of 85.7%. The second column is the group with IGS and 
we would have detected 14(56%) of this category while missing the remaining 
11(44%). The third column is NGT and we would have correctly identified 36(65.45) 
of them while referring the remaining 19(34.55%) for an OGTT. If we had used our 
screening algorithm we would have referred 18 out of 21 patients with DM for an 
OGTT giving us a sensitivity of 85.7%. On the contrary we would not have referred 
36 out of 55 patients with normal OGTT results (65.5%). 
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3-7: Comparison of outcome of WHO 1998 (x-axis) diagnostic criteria with 
screening algorithm (y-axis) at 3 months 
Following is another graphical illustration of the same findings. The first column 
represents group of participants who would have been diagnosed as having DM 
based on elevated FPG. We would have referred the second group for an OGTT and 
it has representation of all the three categories i.e. 19 (45.2%) NGT, 14(33.3%) IGS 
and 9(21.4%)  T2DM. The third column represents patients who would not have 
been referred for OGTT due to our algorithm and we would have missed 3 
participants with DM. The majority of participants in this category were in the NGT 
category 36(72%) with 11(22%) having IGS. In total we would have reduced the 
number of OGTTs from 101 to 42 only (58% reduction). 
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3-8: Comparison of outcome of WHO 1998 (y-axis) diagnostic criteria and 
screening algorithm (x-axis) at 3 months 
 
3.6 Comparison of Screening Algorithm and IEC diagnostic 
criteria: 
 
We also decided to look at how our algorithm would perform compared to the 
newer IEC diagnostic criteria. The two perform quite well paired together and all the 
participants classified as not requiring OGTT based on our algorithm were normal 
on the IEC diagnostic criteria giving a specificity of 100%. On the other hand among 
participants classified as diabetic and not requiring an OGTT according to our 
screening algorithm, 3 (13.6%) were normal according to ADA criteria. 
Following is an illustration of similar data in the form of two graphs. In the first 
graph the left hand column represents those who would be classified as normal 
based on IEC criteria. As illustrated 3 out of those 98 (3%) would have been classed 
as T2DM based on our screening algorithm (FPG=>7 mmol/l). The right hand 
column represents 19 participants who were classified as T2DM based on IEC 
criteria and none of them was missed by our algorithm. 7(37%) would have been 
detected by an elevated FPG and remaining 12(63%) on OGTT results. 
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3-9: Comparison of outcome of HbA1c based diagnostic criteria (x-axis) and 
screening algorithm (y-axis) 
Following is the other graphical illustration of the same findings. The first column 
represents group of participants who would have been diagnosed as having T2DM 
based on elevated FPG.  3 out of the 10 (30%) participants in this category would 
have been missed on IEC criteria. We would have referred the second group for an 
OGTT and it has representation of both categories i.e. 37(75.5%) NGT and 12 (24.5%) 
T2DM. The third column represents patients who would not have been referred for 
OGTT due to our algorithm and we would have missed no participants with T2DM. 
In total as described earlier we would have reduced the number of OGTTs from 118 
to 49 only (58% reduction). 
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3-10: Comparison of outcome of HbA1c based diagnostic criteria (y-axis) and 
screening algorithm (x-axis) 
3.7 Glycaemic changes from baseline to follow-up: 
 
One of the major concerns regarding OGTT has also been its poor reproducibility 
because of the high co-efficient of variation of the 2 hour value. It has also been 
suggested that the timing of the GTT following acute coronary event may be 
important due to possible effects of stress hyperglycaemia. However more recent 
publications have suggested concordance between the GTT results at admission and 
at 3 and 12 months (81). We also decided to look at the possible movements between 
the various groups in our cohort. 
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3-11: Glycaemic changes from baseline to 3 months in the individual groups based 
on WHO 1998 diagnostic criteria. 
Discharge (Normal Glucose Tolerance) 
Total number of patients 57 (10 withdrew)  
38 normal at 2nd visit 4 changed to IFG 5 changed to IGT 
Discharge (IFG) 3 patients  
1 Normal 2 IFG 
Discharge (Impaired Glucose Tolerance)  
Total no of patients 30 (2 deceased, 3 withdrew) 
14 normal
 
 
 
 
 
 
 
  
1 IFG 
 
 
 
4 IGT 
 
1 IFG+IGT 5 Diabetes 
Discharge (IFG+IGT) 5 patients (1 
withdrawn) 
1 normal 2 IFG+IGT 
Discharge (Diabetes) 
23 patients (1 deceased) 
1 normal
 
 
 
 
 
 
 
  
1 IFG 2 IGT 
 
2 IFG+IGT 16 Diabetes 
1 IFG 
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Analysing the data it was clear that 62 (61%) remained similar at 3 months. However 
in 39 participants (39%) the diagnosis was altered at 3 months with the vast majority 
of participants having IGT at baseline changing at 3 months. This could be possibly 
explained by stress hyperglycaemia. In the NGT category 38 (81%) remained similar 
while the remaining 9(19%) changed to IGS at 3 months. In the group with T2DM 
16(73%) remained in the same category while 5(23%) changed to IGT and only 1(4%) 
to NGT. In the third category with IGS only 11(34%) remained similar while 16(50%) 
changed to NGT and 5(16%) changed to T2DM. 
3.8 Urinary cortisol creatinine ratios: 
In order to detect glucocorticoid response to stress I decided to look at estimating 
spot urinary cortisol creatinine ratio at baseline and then repeated it at 3 months. I 
postulated that that it will be positively related to the underlying diagnosis at 
baseline but not follow-up. Following is a basic illustration of the means and 
standard errors (S.E) at baseline and follow-up. 
3-18: Baseline ratio and baseline diagnosis 
Baseline Diagnosis Number Mean ratio S.E 
Diabetes 21 14.22 2.2 
IGS 35 8.29 0.78 
Normal 51 9.03 0.75 
Total 107 9.8 0.64 
  
P =0.016 
3-19: Follow-up ratio and baseline diagnosis 
Baseline Diagnosis Number Mean ratio S.E 
Diabetes 14 11.49 2.49 
IGS 28 8.77 1.52 
Normal 37 11.41 1.37 
Total 79 10.49 0.95 
P=0.41 
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Post-hoc analysis suggested the urinary cortisol creatinine ratio at baseline was 
associated with the glycaemic status at baseline. Following is a tabulated illustration 
of the individual relationships showing the baseline ratio being higher in the 
participants with diabetes compared with both IGS and normal cohorts. (p=0.003 
and 0.005 respectively). 
3-20: Post hoc analysis for baseline ratio and baseline diagnosis 
Dependent Variable Mean Difference of ratio Trend 
Diabetes vs. IGS 5.93 0.003 
Diabetes vs. Normal 5.19 0.005 
IGS vs. Normal -0.74 0.933 
 
3-21: Post hoc analysis for follow-up ratio and baseline diagnosis 
Dependent Variable Mean Difference of ratio Trend 
Diabetes vs. IGS 2.71 0.68 
Diabetes vs. Normal 0.075 1 
IGS vs. Normal -2.64 0.51 
 
I then went on to look at a possible link between spot urinary cortisol creatinine 
ratios and follow-up glycaemic classification. Following is a basic illustration of the 
means and standard errors (S.E) for urinary cortisol creatinine ratios at baseline and 
follow-up between the individual groups. 
3-22: Baseline ratio and follow-up diagnosis 
Follow-up Diagnosis Number Mean ratio S.E 
Diabetes 18 12.21 2.11 
IGS 24 10.68 1.69 
Normal 51 8.54 0.73 
Total 93 9.80 0.73 
P=0.12 
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3-23: Follow-up ratio and follow-up diagnosis 
Follow-up Diagnosis Number Mean ratio S.E 
Diabetes 12 8.8 1.79 
IGS 20 10.54 1.86 
Normal 46 10.99 1.34 
Total 78 10.54 0.96 
 
P=0.74 
Post-hoc analysis did not show a possible association between the ratios and follow-
up glycaemic stratification. Following is a tabulated illustration of the relationships 
between the individual groups suggesting no relationship between the ratios and the 
follow-up diagnosis. 
3-24: Post hoc analysis for baseline ratio and follow-up diagnosis 
Dependent Variable Mean Difference of ratio Trend 
Diabetes vs. IGS 1.53 0.86 
Diabetes vs. Normal 3.67 0.14 
IGS vs. Normal 2.14 0.50 
 
3-25: Post hoc analysis for follow-up ratio and follow-up diagnosis 
Dependent Variable Mean Difference of ratio Trend 
Diabetes vs. IGS -1.69 .93 
Diabetes vs. Normal -2.13 .80 
IGS vs. Normal -.44 .1 
 
To summarise I noted a clear association between spot urinary cortisol creatinine 
ratio at baseline and the baseline diagnosis. 
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Discussion: 
 
I aimed to recruit participants with a wide range of age, sex, ethnic and 
socioeconomic status. However I had a clear majority of white Caucasian males in 
our study. My work is not unique in this regard. Indeed other studies have also 
demonstrated a clear bias towards male recruitment. Study from Holland by de 
Mulder et al had 81% men with 98% being white Caucasian (93). Possible reasons for 
this obvious bias could be the well documented increased risk of cardiovascular 
disease in men compared to women. 
One of the major reasons for the lack of recruitment of the ethnic minority groups 
was that a large proportion of them admitted with ACS were already known to have 
T2DM and therefore automatically excluded. In addition other studies have also 
documented that some of these groups can be difficult to reach for research studies. I 
also noted this despite the ability of members of the research team to speak a variety 
of locally relevant languages. The major risk factor in our study for cardiovascular 
disease appeared to be smoking with at least two thirds of the participants being 
current or ex-smokers. Other studies (93) have also suggested smoking as the 
commonest risk factor although the frequency was 38% compared to our study 
(67%). 
I also noted that in comparison with previous studies (81, 93) the prevalence of 
diabetes was relatively lower in our cohort. Other studies have suggested the 
prevalence being around 33 %( 81) or 35 %( 93) in patients with ACS. This may be 
due to several factors. Firstly because of the nature of our population, a large 
number of participants being admitted to hospital with ACS already had T2DM and 
were therefore automatically excluded. Indeed a previous audit conducted a couple 
of months before starting our project had identified at least 50 patients with DM 
being admitted every month with an ACS. Secondly I also included patients who 
were admitted with non-ST segment elevation myocardial infarction while previous 
studies have mainly focused on patients with ST segment elevation myocardial 
infarction who are at higher risk of diabetes. If I compare my study with de Mulder 
et al they recruited two patient groups i.e. ST segment elevation myocardial 
infarction or troponin positive chest pain (93). In contrast in my study I also included 
participants with chest pain and dynamic ECG changes. This may be a lower risk 
group accounting for a lower prevalence of T2DM. 
As expected, age, BMI and serum fructosamine appeared to have a close relationship 
with glycaemic status with all of them being higher in the groups with T2DM 
compared to NGT or IGS at baseline as well as at follow-up. Previous studies have 
also identified age as being a factor associated with dysglycaemia with de Mulder et 
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al reporting mean age of 71 in the T2DM group compared to 56 and 63 in the NGT 
and IGS groups (93). However they did not find any association with BMI and most 
studies have not reported fructosamine levels. I examined this relationship with age 
in more detail to construct my own diagnostic algorithm in comparison with the 
WHO 1998 diagnostic criteria and this is discussed in more detail in section 5. The 
only other parameter which appeared to be associated with glycaemic status was 
vitamin D status which was higher in the NGT compared to IGS levels. Whilst 
vitamin D levels can be affected by seasonal testing etc. which was not taken into 
account in our study this finding is of some interest since vitamin D has been 
postulated as having anti-oxidant effects as discussed in the introduction. 
One of my main aims was to compare the two currently commonly used diagnostic 
criteria for glucose intolerance. The WHO 1998 and IEC diagnostic criteria gave a 
different prevalence of diabetes in our cohort (20% vs. 16% respectively at baseline 
or 21% vs.16% at 3 months).  As illustrated the two diagnostic criteria appeared to 
identify different cohorts of people with T2DM. The obvious conclusions are that 
while there are some similarities in the patient groups mostly using the two criteria 
we are in fact identifying different cohort of participants. This does raise concerns 
with regards to long term screening in this very high risk group of patients with 
cardiovascular risk factors. In addition by implementing the IEC criteria we are 
potentially missing the group with IGS who are known to be at an increased risk of 
progression to T2DM as well as increased risk of cardiovascular disease and 
mortality. Other studies have also demonstrated similar findings with the 
prevalence of T2DM being only 10% according to IEC criteria in comparison with 
35% according to WHO 1998 diagnostic criteria in one such study (93).  
ADA also recommends pre-diabetes as being 5.7-6.4%. When I looked at a 
comparison between the two pre-diabetes groups from WHO and ADA criteria it 
was obvious that we would be identifying different cohorts with only a third of 
those according to ADA criteria being pre-diabetic according to WHO criteria.  
Our screening algorithm had better sensitivity (87%) in comparison with IEC 
diagnostic criteria (57%) when using WHO criteria as gold standard at baseline. At 3 
months the sensitivity of screening algorithm was 86% in comparison with IEC 
criteria (67%). Previous studies have illustrated similar disparities with one such 
study suggesting sensitivity of IEC criteria being only 29% in comparison with WHO 
diagnostic criteria (93).  In comparison with IEC criteria the sensitivity of our 
screening algorithm was 100%. In addition the algorithm would also lead to around 
60% reduction in the number of patients referred for an OGTT. In the current 
financial climate this has potentially significant cost saving implications. In our own 
Trust the cost of a single OGTT was £62 for analysis only while the cost of the drink 
itself was £7.50. More importantly we are still detecting the majority of participants 
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with T2DM. The main reason for improved performance of the screening algorithm 
was due to the inclusion of FPG in the design of the algorithm. 
Other studies have suggested a better specificity of IEC criteria at 100% compared to 
our study (94%) at baseline (93). However previous studies conducted in this area 
have their own limitations. For example one study only conducted OGTTs at 
hospital discharge and did not follow-up participants therefore possibly having bias 
due to the effects of stress hyperglycaemia (93). A different study which conducted 
OGTTs at baseline and then repeated them at 3 and 12 months, however did not 
compare the two diagnostic criteria (81).My work on the other hand takes these 
factors into account. I have compared the two criteria and also looked at tackling the 
issue of stress hyperglycaemia by repeating an OGTT at 3 months. 
Earlier I mentioned that glycaemic stratification based on WHO 1998 diagnostic 
criteria changed from baseline to 3 months. Closer examination reveals most of the 
patients in the NGT category remained unchanged (81%). While some of the 
participants in the T2DM category also changed (27%) most remained unchanged 
(73%) suggesting in these two categories we could rely on glycaemic classification at 
baseline as a predictor of long term glycaemic status. In comparison most of the 
participants in the IGS category did change (66%) with some of them becoming NGT 
(50%) and some also progressing to T2DM (16%). Previous studies (81) had 
suggested we could rely on glycaemic diagnosis on baseline; however my data 
suggest that at least in the IGS category a second OGTT is required at around 3 
months to predict long term glycaemic diagnosis. This also demonstrates why we 
cannot rely on findings from other studies like de Mulder et al which only rely on 
one OGTT at hospital discharge to detect dysglycaemia not accounting for stress 
hyperglycaemia. 
I measured urinary cortisol creatinine ratio as a possible marker of glucocorticoid 
response to stress. I found a clear association of urinary cortisol creatinine ratio 
being higher in participants with T2DM at baseline compared to IGS and NGT as 
well as those with T2DM at follow-up. This raises the possibility of elevated 
glucocorticoids being part of the reason behind the changes in glycaemic status from 
baseline to follow-up at 3 months. In the previous section, I demonstrated that 30% 
of the participants (7 out of 23) diagnosed with diabetes at baseline did not remain 
diabetic at repeat testing at 3 months. However I did not see a similar association in 
the group of participants with IGS which was the group in whom the majority of 
patients had a change in their glycaemic status. One of the possible limitations of my 
study was the timing of spot urinary collections. For urinary cortisol measurements 
ideally the collections should be early morning, however in a small minority of cases 
I struggled to get the samples at the absolutely correct times. In our study we 
examined the effects of stress by repeating second OGTT at 3 months. It is not 
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entirely clear how long we should wait before repeating the investigations. Some 
studies have looked at 3 and 12 months however other people have also 
recommended 6 weeks. It is also not entirely clear what impact this may have on the 
long term prognosis of these patients. In our study we had 3 patients who passed 
away and all of them had either DM or IGS at diagnosis with at least one of them 
returning to normal at 3 months suggesting the initial changes could have been 
related to a stress related response. This may also be related to how sick some of the 
patients were at their original presentation. Briefly we have suggested a novel 
association between urinary cortisol and glycaemic status in patients admitted to 
hospital with ACS which has not been established before. 
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4. RELATIONSHIP OF 
NOVEL BIOMARKERS 
WITH GLYCAEMIC 
MEASURES 
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4.1 Association of novel biomarkers with individual glycaemic 
measurements: 
 
 In addition to the other biomarkers already described, I also looked for an 
association between novel biomarkers and some of the glycaemic measures used in 
our study.  
These markers included c-peptide, glucagon, interleukin-1RA, adiponectin, leptin, 
pro-insulin, leptin adiponectin ratio, tissue inhibitors of matrix metalloproteinases 1 
and 2 (TIMP 1 and TIMP2) and homeostatic assessment models for insulin 
sensitivity, insulin resistance and beta cell function. I also looked at 3-nitrotyrosine 
as a measure of oxidative stress.  
The following table illustrates the relationship between these biomarkers and some 
of the glycaemic measures at baseline 
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4-1: Association of biomarkers with baseline glycaemic measurements 
Biomarkers and associations Mean 
Baseline 
FPG 
Mean 
Baseline 2-hr 
PG 
Mean 
Baseline 
HbA1c 
C-peptide    Pearson Correlation            
Sig                                                          
Number 
.41        
<0.0001
81 
.41           
<0.0001          
81 
.41            
<0.0001           
81 
Glucagon     Pearson Correlation               
Sig                                                         
Number 
.13              
.2   
80 
.25                   
.02                      
80 
.12                    
.3                      
80 
3 NT             Pearson Correlation               
Sig                                                         
Number 
-.013               
.9
99 
-.014                  
.7                      
99 
.1                   
.3                       
98 
Adiponectin  Pearson Correlation             
Sig                                                          
Number 
-.19             
.09   
81 
-.03                    
.8                         
81 
-.05                   
.7                      
81 
Leptin            Pearson Correlation            
Sig                                                         
Number 
0.14              
.2   
80 
0.24                 
.03                   
80 
0.12               
.3                   
80 
IL 1 RA         Pearson Correlation               
Sig                                                            
Number 
0.17            
0.19
60 
0.29                 
.02                  
60 
0.33             
.009              
60 
TIMP 1         Pearson Correlation                  
Sig                                                            
Number 
-.06               
.6
81 
0.22                 
.05                    
81 
0.03                
.8                  
81 
TIMP 2         Pearson Correlation                      
Sig                                                          
Number 
-.02        
0.8
81 
.09                 
0.4                   
81 
0.12               
0.3                 
81 
Pro-insulin  Pearson Correlation             
Sig                                                            
Number 
0.39    
<0.0001  
78 
0.49       
<0.0001          
78 
0.40     
<0.0001       
78 
L/A ratio     Pearson  Correlation              
Sig                                                      
Number 
0.12          
0.29    
79 
0.25             
0.03                 
79 
0.11           
0.31              
79 
HOMA I.R  Pearson Correlation            
Sig                                                          
Number 
0.44  
<0.0001    
80 
0.37           
0.001              
80 
0.27            
0.017            
80 
HOMA β       Pearson Correlation          
Sig                                                             
Number 
-0.398 
<0.0001     
80 
-0.18            
0.12                
80 
-0.298     
0.007            
80 
HOMA I.S    Pearson Correlation          
Sig                                                       
Number 
-0.376   
0.001   
80 
-0.321        
0.002              
80 
-0.21         
0.06              
80 
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I noted interesting correlations for a number of these biomarkers. Mean c-peptide 
was noted to be positively associated with mean baseline fasting and 2 hour PG, as 
well as HbA1c (p=<0.0001). 
Mean glucagon, leptin and leptin adiponectin ratio were noted to be positively 
associated with mean baseline 2 hour PG levels (p=0.02, 0.03 and 0.03 respectively).  
Mean Interleukin-1RA was positively associated with mean baseline 2 hour PG as 
well as HbA1c (p=0.023 and 0.009 respectively). 
 Mean TIMP 1 was positively related to mean baseline 2 hour PG (p=0.049). I did not 
see any relationship between TIMP 2, 3 NT or adiponectin and any of the mean 
glycaemic markers. 
Mean intact pro-insulin levels were positively related to mean baseline FPG, 2 hour 
PG, as well as HbA1c (p<0.0001). 
Insulin resistance was noted to be positively associated with all the mean baseline 
variables FPG, 2 hr PG and HbA1c (p<0.0001, 0.001 and 0.017 respectively).  
Insulin sensitivity was negatively associated to the glycaemic markers including 
mean baseline FPG and 2 hour PG (p=0.001 and 0.002 respectively) On the other 
hand beta cell function was negatively associated with mean baseline FPG and 
HbA1c only (p<0.0001 and 0.007 respectively).  
I than went on to look at the relationship between these biomarkers and the follow-
up glycaemic measures including mean follow-up FPG and 2 hour PG. Following 
table illustrates the relationship between them in detail. 
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4-2: Association of biomarkers with follow-up glycaemic measurements 
Biomarkers and associations Mean Follow-up FPG Mean Follow-up 2-hr PG 
C-peptide    Pearson Correlation                                
Sig                                                            
Number 
0.26                   
0.04                  
62 
0.25                                  
0.05                                    
61 
Glucagon     Pearson Correlation           
Sig                                                          
Number 
.13                                 
0.3                    
61 
.33                                 
0.009                                  
60 
3 NT             Pearson Correlation            
Sig                                                          
Number 
-.01                               
0.9                    
79 
-.09                                    
0.4                                          
78 
Adiponectin  Pearson Correlation               
Sig                                                       
Number 
-0.2                                
0.1                       
62 
-0.2                                    
0.1                                       
61 
Leptin            Pearson Correlation          
Sig                                                         
Number 
0.17                              
0.2                       
61 
0.31                                 
0.02                                    
60 
IL 1 RA         Pearson Correlation              
Sig                                                        
Number 
0.32                              
0.03                      
44 
0.17                                  
0.23                                        
43 
TIMP 1         Pearson Correlation            
Sig                                                      
Number 
0.16                              
0.2                        
62 
0.13                                   
0.3                                      
61 
TIMP 2         Pearson Correlation              
Sig                                                         
Number 
0.11                            
0.38                      
81 
0.19                                 
0.14                                    
81 
Pro-insulin  Pearson Correlation             
Sig                                                       
Number 
0.14                               
0.3                        
61 
0.35                               
0.006                                    
60 
L/A ratio     Pearson  Correlation                      
Sig                                                       
Number 
0.15                           
0.25                       
60 
0.38                                
0.003                                  
59 
HOMA I.R   Pearson Correlation                 
Sig                                                      
Number 
0.30                                
0.01                           
60 
0.28                                  
0.03                                     
59 
HOMA β     Pearson Correlation              
Sig                                                          
Number 
-0.1                              
0.4                     
60 
-0.05                                    
0.7                                        
59 
HOMA I.S   Pearson Correlation             
Sig                                                            
Number 
-0.35                            
0.006                       
62 
-0.27                                   
0.03                                       
61 
 
 Mean c-peptide and HOMA I.R were positively associated with mean follow-up 
FPG and 2 hour PG (p=0.04 and 0.05 for C peptide and 0.01 and 0.03 for I.R 
respectively). Similarly HOMA I.S was negatively associated with both variables 
(p=0.006 and 0.03 for FPG and 2 hour PG). 
Mean glucagon, leptin, pro-insulin and leptin adiponectin ratio were positively 
associated with mean 2 hour PG at follow-up (p=0.009, 0.02, 0.006 and 0.003 
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respectively). IL 1RA was positively associated with the follow-up FPG only 
(p=0.03). 
I did not observe any association between 3 NT, adiponectin, TIMP 1 and TIMP 2 
and any of the glycaemic measures at follow-up. I wanted to look at the baseline 
associations after adjusting for some of the background variables. As a first step I 
adjusted for age, body mass index, sex and ethnicity. The following table illustrates 
these associations after correcting for the above 4 parameters.  
4-3: Association of biomarkers with baseline glycaemic measurements after 
adjusting for age, BMI, sex and ethnicity 
Biomarkers and associations Mean 
baseline 
FPG 
Mean baseline 
2-hr PG 
Mean 
baseline 
HbA1c 
C-peptide    Correlation                                  
Sig 
.32        
0.007 
.34             
0.005 
.34           
0.005 
Glucagon     Correlation                          
Sig 
.05            
.69 
0.19             
0.12 
0.05            
0.69 
3 NT              Correlation                          
Sig 
-0.04      
0.72 
-0.07            
0.49 
0.09           
0.41 
Adiponectin  Correlation                           
Sig 
-0.15      
0.23 
-.04              
0.76 
-.002         
0.99 
Leptin            Correlation                         
Sig 
-0.03      
0.82 
0.04               
.76 
-0.06         
0.63 
IL 1 RA         Correlation                          
Sig 
0.08         
0.56 
0.17             
0.23 
0.27           
0.05 
TIMP 1          Correlation                          
Sig 
-0.076     
0.54 
0.19             
0.11 
0.006           
.96 
TIMP 2         Correlation                                 
Sig 
-0.11         
0.38 
-0.08            
0.50 
0.04           
0.73 
Pro-insulin   Correlation                          
Sig 
0.32         
0.009 
0.47             
<0.0001 
0.35         
0.005 
L/A ratio     Correlation                            
Sig 
-0.05         
0.65 
0.095           
0.45 
-0.05           
0.7 
HOMA I.R  Correlation                           
Sig 
0.38             
0.002 
0.33           
0.007 
0.18           
0.14 
HOMA β     Correlation                                 
Sig 
-0.51 
<0.0001 
-0.28              
0.02 
-0.39              
0.001 
HOMA I.S   Correlation                                 
Sig 
-0.304          
0.01 
-0.26              
0.04 
-0.12                  
0.33 
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Mean c-peptide, intact pro-insulin levels and beta cell function still remained 
associated with all the baseline glycaemic measurements i.e. mean baseline FPG, 2 
hour PG and HbA1c (p=0.007, 0.005 and 0.005 for C-peptide, p=0.009, < 0.0001 and 
0.005 for pro-insulin and <0.0001, 0.02 and 0.001 for beta cell function respectively). 
Beta cell function had a negative correlation while others were positive. 
Insulin resistance and beta cell sensitivity were still associated with the baseline FPG 
and 2 hour PG (p=0.002 and 0.007 for I.R and p=0.01 and 0.04 for HOMA I.S 
respectively). Insulin sensitivity had a negative while HOMA I.R had a positive 
association with the glycaemic measurements. IL 1RA also still remained positively 
associated with the baseline HbA1c (p=0.05). 
The associations for other biomarkers such as glucagon, leptin, leptin adiponectin 
ratio and TIMP 1 were lost after adjusting for age, BMI sex and ethnicity.  
I decided to look at these confounders individually and it appeared that BMI was the 
main confounding variable for most of these biomarkers. Following table illustrates 
this in detail as it shows the associations after adjusting for age, sex and ethnicity 
only.  
As illustrated in the table, after adjusting for age, sex and ethnicity the associations 
for glucagon, leptin and leptin adiponectin ratio still remained suggesting BMI as 
being the main confounder as expected for leptin and adiponectin.  
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4-4: Association of biomarkers with baseline glycaemic measures after adjusting 
for age, sex and ethnicity. 
Biomarkers and associations Baseline 
FPG 
Baseline 2-hr 
PG 
Baseline 
HbA1c 
C-peptide    Correlation                                 
Sig 
.40  
<0.0001 
.44         
<0.0001 
.41      
<0.0001 
Glucagon     Correlation                          
Sig 
0.1            
.38 
0.25               
0.03 
0.1                  
0.38 
3 NT              Correlation                          
Sig 
-0.04            
0.72 
-0.07              
0.49 
0.08                 
0.44 
Adiponectin  Correlation                          
Sig 
-0.24          
0.04 
-0.17              
0.14 
-0.10              
0.38 
Leptin            Correlation                           
Sig 
0.16          
0.18 
0.26                 
0.02 
0.13                  
0.28 
IL 1 RA         Correlation                            
Sig 
0.19           
0.16 
0.29                 
0.03 
0.35                    
0.008 
TIMP 1          Correlation                            
Sig 
-0.07      
0.54 
0.18             
0.11 
0.007           
.95 
TIMP 2         Correlation                              
Sig 
-0.09       
0.41 
-0.07            
0.56 
0.05            
0.67 
Pro-insulin   Correlation                          
Sig 
0.38            
0.001 
0.52                               
<0.0001 
0.39          
0.001 
L/A ratio       Correlation                          
Sig 
0.13              
0.28 
0.29                 
0.01 
0.13           
0.28 
HOMA I.R    Correlation                             
Sig 
0.44 
<0.0001 
0.42            
<0.0001 
0.27              
0.02 
HOMA β      Correlation                               
Sig 
-0.43    
<0.0001 
-0.19            
0.09 
-0.32             
0.005 
HOMA I.S    Correlation                           
Sig 
-0.37          
0.001 
-0.36            
0.002 
-0.21                
0.07 
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4.2 Relationship of novel biomarkers with glycaemic 
classification based on WHO 1998 diagnostic criteria: 
I next compared these biomarkers with baseline glycaemic stratification based on 
WHO 1998 diagnostic criteria as illustrated below.  
4-5: Mean levels of biomarkers in the individual groups based on WHO 1998 criteria at baseline 
Variables Number Mean S.E 
C-peptide                  DM                                     
IGS                                                              
Normal 
18     
20   
43 
3654.2 
2870.4 
2501.5 
602          
209            
206 
Glucagon                  DM                                       
IGS                                                                
Normal 
18                
20
42 
82.9          
75.4        
59.6 
14.8            
5.9              
3.6 
3 NT                          DM                                      
IGS                                                               
Normal 
18                  
34
47 
28.9           
28.7           
27.7 
4.5               
2.3               
2.2 
Adiponectin             DM                                       
IGS                                                                  
Normal 
18                     
20
43 
3.9              
4.1            
3.6 
0.6              
0.8                
0.26 
Leptin                      DM                                     
IGS                                                                  
Normal 
18      
19
43 
18.7          
19.5           
11.1 
3.4              
4.4               
1.2 
IL-1RA                     DM                                   
IGS                                                                
Normal 
12           
17
31 
0.35            
0.36          
0.26 
.06              
.05                
.03 
TIMP-1                    DM                                    
IGS                                                                
Normal 
18                
20  
43 
112.7        
94.5         
92.8 
12                     
6                   
5 
TIMP-2                     DM                                      
IGS                                                                 
Normal 
18        
20
43 
76.6        
75.8          
71.7 
3.3              
1.7             
1.9 
Pro-insulin              DM                                             
IGS                                                                  
Normal 
18
19
41 
15.7            
8.3         
6.6 
3.7              
1.6                    
.8 
Lep/Ad ratio          DM                                 
IGS                                                             
Normal 
18          
19        
42 
6.2            
8                   
3.6 
1.2             
2.0                
.4 
I.R                             DM                                 
IGS                                                                
Normal 
17          
20
43 
2.5             
2.2         
1.8 
.27             
.16              
.15 
Β-fun                        DM                                 
IGS                                                             
Normal 
17          
20
43 
104.6 
130.8 
130.0 
8.4            
8.6                
7 
I.S                            DM                                    
IGS                                                              
Normal 
17         
20
43 
50.5         
51.9          
69.9 
6.9             
4.5               
6 
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4-6: Strength of association between biomarkers and baseline diagnosis 
BIOMARKERS SIGNIFICANCE OF TREND (p values) 
C-peptide 0.04 
Glucagon 0.05 
3 NT 0.94 
Adiponectin 0.77 
Leptin 0.04 
IL 1 RA 0.13 
TIMP 1 0.32 
TIMP 2 0.35 
Pro-insulin 0.02 
Leptin adiponectin ratio 0.03 
HOMA IR 0.04 
HOMA β 0.09 
HOMA IS 0.05 
 
I noted that mean c-peptide, glucagon, intact pro-insulin and HOMA IR were higher 
in the diabetic group compared to normal and IGS groups. (p=0.04, 0.05, 0.02 and 
0.04 respectively)I also noted a trend for leptin and leptin adiponectin ratio to be 
higher in both diabetic and IGS groups compared to normal groups (p=0.04 and 0.03 
respectively).The only other biomarker which showed a clear association was 
HOMA IS which was noted to be lower in the diabetic and IGS groups compared to 
normal cohort (p=0.05). 
I than went on to compare these biomarkers with follow-up glycaemic stratification 
based on W.H.O 1998 diagnostic criteria. Following 2 tables illustrate the mean 
values along with standard error and the significance of the association. 
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4-7: Mean levels of biomarkers in the individual groups based on WHO 1998 diagnostic criteria at 
3 months 
Variables Number Mean S.E 
C-peptide                  DM                               
IGS                                                                
Normal 
16                
14
38 
2548.8   
1204.3 
1402.3 
637.2     
321.8     
227.5 
Glucagon                  DM                                   
IGS                                                               
Normal 
16                 
14
37 
73.9           
87.9        
58.7 
8.1            
18.3                
3.7 
3 NT                          DM                                 
IGS                                                            
Normal 
15               
22   
47 
29.5      
26.1        
29.1 
4.7             
3.0            
2.4 
Adiponectin             DM                                
IGS                                                                 
Normal 
16              
14
38 
3.3          
3.4         
3.9 
0.6               
0.4                
0.37 
Leptin                      DM                                    
IGS                                                                 
Normal 
16        
14
37 
18.9         
15.2         
13.5 
3.5               
3.0              
1.9 
IL-1RA                     DM                                  
IGS                                                            
Normal 
12           
9   
28 
0.41          
0.27         
0.27 
.06            
.05                  
.03 
TIMP-1                    DM                                    
IGS                                                            
Normal 
16              
14  
38 
105.5         
98.4        
94.8 
8.2           
10.6            
6.1 
TIMP-2                     DM                                   
IGS                                                             
Normal 
16         
14
38 
70.8        
73.8        
70.7 
2.9              
1.8                 
1.7 
Pro-insulin              DM                                    
IGS                                                                 
Normal 
16         
14
36 
15.5          
8.3            
7.0 
3.6                
1.9             
1.1 
Lep/Ad ratio          DM                                  
IGS                                                            
Normal 
16           
14       
36 
6.5            
5.5               
4.5 
1.2                 
1.1                     
.8 
I.R                             DM                                    
IGS                                                            
Normal 
15           
14    
38 
2.6            
1.96            
1.86 
.22            
.25               
.17 
HOMA β                DM                                   
IGS                                                                    
Normal 
15          
14
38 
108.9 
118.6 
131.5 
10.5          
8.9                
7.9 
HOMA I.S               DM                                 
IGS                                                                
Normal 
15          
14
38 
46.1         
58.9         
69.4 
5.7             
5.7               
5.9 
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4-8: Strength of association between biomarkers and baseline diagnosis 
BIOMARKERS SIGNIFICANCE OF ASSOCIATION(p values) 
C-peptide 0.05 
Glucagon 0.11 
3 NT 0.75 
Adiponectin 0.54 
Leptin 0.33 
IL 1 RA 0.05 
TIMP 1 0.63 
TIMP 2 0.01 
Pro-insulin 0.02 
Leptin adiponectin ratio 0.37 
HOMA IR 0.07 
HOMA β 0.23 
HOMA IS 0.05 
 
I noted that mean c-peptide, IL 1 RA, TIMP 2 and intact pro-insulin were higher in 
the diabetic group compared to normal and IGS groups. (p=0.05, 0.05, 0.01 and 0.02 
respectively). The only other trend noticed was for HOMA IS to be lower among 
diabetics (p=0.05) 
4.3 Comparison of individual NGT, IGS and T2DM Groups: 
                                                                                                                                        
I decided to compare the three individual groups with respect to the movements 
within these groups. The first group we compared was the DM group. We noted 
higher adiponectin, HOMA I.S and TIMP 1 levels among NGT and IGS compared to 
DM group in this cohort at 3 months. 
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4-9: Mean levels of biomarkers in the DM group based on WHO 1998 diagnostic criteria at 3 months 
Variables Number Mean S.E 
C-peptide                  DM                                                           
IGS                                                                                        
Normal 
12
4            
1 
3920.7 
3184.2 
1139.9 
836.1         
881.1 
Glucagon                  DM                                         IGS                                                                     
Normal 
12
4                          
1 
72.1
127             
48.5 
8.8                      
62.1 
3 NT                          DM                                                            
IGS                                                                                  
Normal 
12               
4                 
1 
31.2         
23.9          
23.3 
5.8                     
11.5 
Adiponectin             DM                                                          
IGS                                                                                  
Normal 
12                      
4               
1 
3.7             
2.5            
12.7 
0.5                  
0.4 
Leptin                      DM                                                             
IGS                                                                                        
Normal 
12
4    
1 
20.3          
20.1            
2.2 
4.5                   
6.5 
TIMP-1                    DM                                                              
IGS                                                                                        
Normal 
12                     
4
1 
105.7          
111.5         
244.6 
10.6              
27.4 
TIMP-2                     DM                                                             
IGS                                                                                 
Normal 
12
4
1 
79.9         
67.2          
93.8 
3.8                 
4.6 
Pro-insulin              DM                                                         
IGS                                                                                   
Normal 
12     
4
1 
16.9              
15.4                 
3.2 
4.7                 
6.7 
Lep/Ad ratio          DM                                                            
IGS                                                                                       
Normal 
12
4
1 
6.1                  
8.5           
0.17 
1.5                  
2.5 
I.R                             DM                                                     
IGS                                                                                        
Normal 
11        
4      
1 
2.6             
2.3              
0.8 
0.3                  
0.7 
HOMA β                   DM                                                         
IGS                                                                                        
Normal 
11    
4
1 
95.8           
122.2          
113.2 
9.4               
22.2 
HOMA I.S               DM                                                            
IGS                                                                                      
Normal 
11   
4        
1 
45.5          
51.7           
126 
6.9                     
9.9 
Age                          DM                                                              
IGS                                                                                     
Normal 
16                       
5
1 
67.7             
61.8             
76 
3.2                 
5.7 
BMI                         DM                                                               
IGS                                                                                 
Normal 
15     
5
1 
31.6            
30.4             
17 
1.5                 
4.4 
FPG                         DM                                                             
IGS                                                                                    
Normal 
16  
5       
1 
7.5             
5.8              
4.3 
0.55                
0.2 
2hr PG                     DM                                                             
IGS                                                                                  
Normal 
16               
5       
1 
15.3             
12.7             
12 
1.1                 
0.3 
HbA1c                     DM                                                                 
IGS                                                                                 
Normal 
16
5        
1 
7.5              
6.1             
6.2 
0.4                 
0.2 
Fructosamine         DM                                                       
IGS                                                                                
Normal 
11                     
4       
1 
239.7          
218.2         
246 
17.1                
8.6 
Systolic B.P                   DM                                                        
IGS                                                                                     
Normal 
15  
5       
1 
129.1         
133.6           
103 
4.9               
11.5 
Diastolic B.P                    DM                                               
IGS                                                                                
Normal 
15            
5
1 
77.5            
72.6            
78 
2.6                 
6.9 
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4-10: Strength of association between biomarkers and baseline diagnosis 
BIOMARKERS SIGNIFICANCE (p values) 
C-peptide 0.59 
Glucagon 0.31 
3 NT 0.80 
Adiponectin <0.001 
Leptin 0.51 
IL 1 RA 0.13 
TIMP 1 0.02 
TIMP 2 0.13 
Pro-insulin 0.75 
Leptin adiponectin ratio 0.37 
HOMA IR 0.27 
HOMA β 0.46 
HOMA IS 0.01 
Age 0.52 
BMI 0.15 
FPG 0.12 
2 hr PG 0.34 
HbA1c 0.14 
Fructosamine 0.75 
Systolic B.P 0.42 
Diastolic B.P 0.7 
 
I than went on to compare the IGS group and looked at the three groups within this 
group at 3 months. TIMP 2 levels were lower in the NGT group compared to IGS 
and DM groups. There was also a trend towards higher FPG and systolic B.P in the 
IGS group compared to NGT and DM groups. Following is a tabulated illustration of 
this cohort 
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4-11: Mean levels of biomarkers in the IGS group based on WHO 1998 diagnostic criteria at 3 months 
Variables Number Mean S.E 
C-peptide                  DM                                                             IGS                                                                                     
Normal 
4           5       
8 
3190.3 2702.3
2769.1 
544.5          583.5           
296.1 
Glucagon                  DM                                                        IGS                                                                                
Normal 
4 5
8 
79.5          78.4      
71.9 
21                10.4               
9.5 
3 NT                          DM                                                    IGS                                                                                
Normal 
3              10                    
15 
23 27        
30.9 
0.99               4.4                       
4 
Adiponectin             DM                                                    IGS                                                                                
Normal 
4 5
8 
1.97      4.9             
3.2 
0.29               1.5                 
0.7 
Leptin                      DM                                                      IGS                                                                                
Normal 
4 5
7 
15      14.6        
22.2 
4.1                 5.3                 
7.7 
TIMP-1                    DM                                                       IGS                                                                                
Normal 
4                         5                         
8 
104.9
89.9            91.1 
10.4             15.3                  
11 
TIMP-2                     DM                                                          IGS                                                                                
Normal 
4                       5                          
8 
83.6 82.5    
61.6 
2                     4.8                 
2.1 
Pro-insulin              DM                                                         IGS                                                                                
Normal 
4             5                      
7  
11.3 6         
8.9 
3.3                 1.8                  
3.9 
Lep/Ad ratio          DM                                                     IGS                                                                                
Normal 
4 5
7 
7.4           4                
9.3 
1.4               1.36                
3.2 
I.R                             DM                                                            IGS                                                                                 
Normal 
4 5          
8 
2.4 2.1   
2.1 
0.42                 
0.47              0.24 
HOMA β                   DM                                                    IGS                                                                                   
Normal 
4 5
8 
145            107          
137 
22.6             11.7             
14.2 
HOMA I.S               DM                                                        IGS                                                                                   
Normal 
4 5
8 
47.6 59.8
51.7 
11.7             14.4                
4.9 
Age                          DM                                                        IGS                                                                                
Normal 
5 11
16 
59.6             
64.3          60.7 
4.5                  2.5                 
2.1 
BMI                         DM                                                       IGS                                                                                    
Normal 
5 10
15 
32       28.8       
29 
2                      0.9                 
1.2 
FPG                         DM                                                       IGS                                                                                
Normal 
5 11
16 
5.36           5.85      
5.34 
0.18             0.18             
0.14 
2hr PG                     DM                                                              IGS                                                                                     
Normal 
5 11
16 
9.6             8.3             
8.8 
0.5                0.3                  
0.3 
HbA1c                     DM                                                         IGS                                                                                
Normal 
5                      11                       
16 
6.4 6.0      
6.0 
0.3                   0.1                
0.06 
Fructosamine         DM                                                            IGS                                                                                       
Normal 
5 8
9 
213.8   214.1       
200.3 
10.6                7.9                 
5.1 
Systolic B.P                    DM                                                  IGS                                                                                      
Normal 
5                       11                   
16 
114 135
119 
6.9                 6.8                    
4.3 
Diastolic B.P                    DM                                             IGS                                                                                     
Normal 
5 11
16 
74.6             
75.3          74.2 
4                    4.8                 
3.5 
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4-12: Strength of associations 
BIOMARKERS SIGNIFICANCE (p values) 
C-peptide 0.75 
Glucagon 0.89 
3 NT 0.62 
Adiponectin 0.18 
Leptin 0.66 
IL 1 RA 0.53 
TIMP 1 0.71 
TIMP 2 <0.001 
Pro-insulin 0.63 
Leptin adiponectin ratio 0.36 
HOMA IR 0.78 
HOMA β 0.29 
HOMA IS 0.71 
Age 0.48 
BMI 0.34 
FPG 0.06 
2 hr PG 0.12 
HbA1c 0.15 
Fructosamine 0.32 
Systolic B.P 0.06 
Diastolic B.P 0.98 
 
I than went on to look at the NGT group and compared the cohorts which remained 
normal with those that developed IGS.  The only trend was diastolic B.P being 
higher in the normal compared to IGS groups. Following is a tabulated illustration of 
the findings: 
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4-13: Mean levels of biomarkers in the NGT group based on WHO 1998 diagnostic criteria at 3 months 
Variables Number Mean S.E 
C-peptide                   IGS 
Normal 
5 
29 
2149.1 
2481.7 
126.9 
283.8 
Glucagon                   IGS 
Normal 
5 
28 
65.9 
55.2 
13.1 
3.9 
3 NT                          IGS 
Normal 
8 
31 
26.1 
28.4 
4 
3.1 
Adiponectin             IGS 
Normal 
5 
29 
2.7 
3.8 
0.44 
0.32 
Leptin                      IGS 
Normal 
5 
29 
11.8 
11.8 
4.6 
1.4 
IL-1RA                     IGS 
Normal 
3 
20 
0.28 
0.27 
0.08 
0.03 
TIMP-1                     IGS 
Normal 
5 
29 
96.5 
90.7 
17 
5.3 
TIMP-2                     IGS 
Normal 
5 
29 
70.6 
72.4 
2.3 
1.9 
Pro-insulin              IGS 
Normal 
5 
28 
4.9 
6.7 
1.2 
1.1 
Lep/Ad ratio          IGS 
Normal 
5 
28 
4.6 
3.5 
1.6 
0.44 
I.R                             IGS 
Normal 
5 
29 
1.56 
1.8 
0.08 
0.2 
HOMA β                 IGS 
Normal 
5 
29 
127.3 
130.6 
13.6 
9.1 
HOMA I.S               IGS 
Normal 
5 
29 
63.9 
72.3 
3.3 
7.3 
Age                          IGS 
Normal 
9 
38 
56.7 
58.7 
3.7 
1.8 
BMI                         IGS 
Normal 
9 
35 
27.2 
27.2 
1.3 
0.78 
FPG                          IGS 
Normal 
9 
38 
5.18 
5.19 
0.13 
0.06 
2hr PG                    IGS 
Normal 
9 
38 
6 
5.9 
0.29 
0.21 
HbA1c                     IGS 
Normal 
9 
38 
5.8 
5.76 
0.13 
0.04 
Fructosamine         IGS 
Normal 
6 
30 
208 
207.2 
6.2 
3.1 
Systolic B.P                     IGS 
Normal 
9 
37 
122 
127 
5.2 
3.3 
Diastolic B.P                     IGS 
Normal 
9 
37 
68 
75.5 
2.6 
1.9 
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4-14: Strength of association between biomarkers and baseline diagnosis 
BIOMARKERS SIGNIFICANCE (p values) 
C-peptide 0.63 
Glucagon 0.32 
3 NT 0.73 
Adiponectin 0.17 
Leptin 0.98 
IL 1 RA 0.95 
TIMP 1 0.69 
TIMP 2 0.69 
Pro-insulin 0.51 
Leptin adiponectin ratio 0.37 
HOMA IR 0.59 
HOMA β 0.89 
HOMA IS 0.64 
Age 0.63 
BMI 0.98 
FPG 0.97 
2 hr PG 0.89 
HbA1c 0.73 
Fructosamine 0.92 
Systolic B.P 0.53 
Diastolic B.P 0.07 
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Discussion: 
 
 I examined the relationship between individual glycaemic measures and novel bio-
markers. At baseline I found a clear positive association between fasting plasma 
glucose and c-peptide, pro-insulin, HOMA I.R and HOMA β. In contrast HOMA I.S 
was negatively associated with baseline FPG. The post-load glucose concentrations 
were positively associated with the vast majority of variables including C-peptide, 
pro-insulin, glucagon, leptin, leptin adiponectin ratio, HOMA I.R, TIMP-1 and IL-Ira. 
HOMA I.S was negatively associated with post-load glucose. The HbA1c on the 
other hand was positively associated with C-peptide, pro-insulin, HOMA I.R, 
HOMA β and IL-Ira. These findings suggest the role some of these variables can play 
in predicting glycaemic abnormalities in patients with ACS.  
The 2 hour plasma glucose was the most consistently associated variable with the 
pancreatic and insulin related biomarkers. Part of this could be related to stress 
hyperglycaemia. However apart from an association of glucagon levels with urinary 
cortisol creatinine concentrations at baseline I was unable to demonstrate any other 
associations between these markers. Earlier in the first chapter I have mentioned 
studies have suggested a clear association between elevated post-load glucose 
concentrations and cardiovascular mortality.  
The HOMA IR was used as a marker of insulin resistance as other measures such as 
euglycaemic hyperinsulinaemic clamp study are too expensive and technically 
demanding to conduct (182). Some studies have also demonstrated association of c-
peptide and HOMA-IR with all cause and cardiovascular mortality. These studies 
have looked at them independent of other factors such as BMI and increased waist 
hip ratio and still found that all-cause mortality is independently predicted (181, 
183). 
One of the novel aspects of my work is that I also studied these relationships at 3 
months after the initial cardiovascular event in contrast with other studies which 
only looked at measuring glycaemic status at baseline (93). At 3 months I noted the 
FPG was positively associated with c-peptide and IL-IRA and negatively associated 
with HOMA I.S. On the other hand 2 hour plasma glucose was associated with C-
peptide, pro-insulin, HOMA I.R, leptin, leptin adiponectin ratio and glucagon 
positively and with HOMA I.S negatively. The association of glucagon, leptin and 
leptin adiponectin ratio appears to be driven by the BMI as demonstrated by logistic 
regression analysis.  
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I also examined the relationship between the pancreatic biomarkers and glycaemic 
stratification according to WHO diagnostic criteria. C-peptide, pro-insulin and 
HOMA I.S were the three biomarkers related to both baseline and follow-up 
diagnosis with c-peptide and pro-insulin being higher and HOMA I.S lower among 
those with T2DM. This suggests insulin resistance and sensitivity being the main 
parameters associated with baseline and follow-up glycaemic status. By contrast 
leptin, glucagon, leptin adiponectin ratio and HOMA I.R were associated with 
baseline diagnosis only. IL-1RA and TIMP-2 were associated with follow-up 
diagnosis only.  
These findings suggest we can in future potentially look at utilizing some of the 
markers of insulin production and sensitivity as helpful in predicting future 
glycaemic status. I will explore this in more detail in the next section where we tried 
to utilize some of these biomarkers in designing our novel formula i.e. Diabetes 
Predictor Score.  
In the previous section I demonstrated that there were movements between 
individual groups according to WHO 1998 diagnostic criteria from baseline to 
follow-up at 3 months. Although the importance of treating elevated plasma glucose 
during admissions with cardiovascular disease is accepted, it is also important to 
determine long term glycaemic status. I analysed the three groups individually to 
check if any measurements could help predict long term glycaemic status. 
Previous studies of assessing dysglycaemia in ACS demonstrated that those with 
T2DM who remain diabetic long term have higher HbA1c, triglycerides and HOMA 
I.R and lower IGI (81). In my study I noted that in this group patients who remained 
diabetic at 3 months had lower adiponectin and TIMP 1 and lower HOMA I.S. This 
would suggest that performing a complete metabolic profile assessment can provide 
useful information in predicting long term glycaemic status. 
In subjects with IGS, I noted TIMP 2 levels were lower in those who became NGT at 
3 months. There was also a trend towards higher FPG and systolic B.P in the IGS 
group compared to NGT and DM groups. In the NGT group there were no 
statistically significant differences between the NGT and IGS groups.  
We have to accept limitations of our study in this regard as the number of 
participants in each group were very few. Ideally we would have liked to recruit 
more participants in each category so that our subsequent sub-analysis would have 
more strength. We were surprised to find no significant associations of parameters 
such as HbA1c and fructosamine as well as urinary cortisol creatinine 
concentrations. However this is likely to be due to the lack of statistical power. 
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5. DIABETES 
PREDICTOR SCORE 
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5.1 Diabetes Predictor Score: 
My aim was to determine whether a score could be designed to diagnose diabetes 
with improved sensitivity and specificity compared to IEC criteria and the screening 
algorithm using the W.H.O 1998 diagnostic criteria as gold standard. I looked at 
various parameters including age, BMI, sex, ethnicity, FPG, HbA1c, novel 
biomarkers, nature of the cardiac event as well as serum fructosamine by using 
logistic regression. However I was unable to utilize some of the parameters like 
fructosamine and the pancreatic and insulin related biomarkers as they were not 
available for all the participants. The following table illustrates the relationship of 
glycaemic measures and background parameters like age, sex, BMI and nature of the 
cardiac event. 
5-1: Initial Logistic regression table for computing Diabetes Predictor Score 
Variable Regression 
co-efficient 
Standard 
Error 
Significance 
(p value) 
Odds ratio Confidence 
interval 
Age 0.11 0.04 0.008 1.1 1.03-1.30 
BMI 0.05 0.08 0.49 1.0 0.90-1.24 
Sex 0.84 1.0 0.40 2.3 0.32-16.7 
FPG 1.7 0.57 0.003 5.5 1.8-16.9 
HbA1c 1.7 0.75 0.025 5.4 1.2-23.7 
Cardiac event -0.5 0.76 0.46 0.57 0.13-2.52 
 
The best predictors appeared to be age, FPG and HbA1c. We did initially include 
BMI as we thought it would have a clear impact, however as shown in Table 2, BMI 
did not appear to have a positive correlation. The equation we designed was as 
follows: 
Diabetes predictor score= (0.1 * Age) + (1.7 * FPG) + (1.6 * HbA1c). 
5-2: Final Logistic regression table for computing Diabetes Predictor Score 
Variable Regression 
co-efficient 
Standard 
Error 
Significance 
(p value) 
Odds ratio Confidence 
interval 
Age 0.1 0.04 0.007 1.1 1.03-1.19 
BMI 0.05 0.08 0.49 1.0 0.91-1.23 
FPG 1.7 0.54 0.002 5.4 1.89-15.8 
HbA1c 1.6 0.7 0.03 4.8 1.19-19.1 
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ROC curve for comparison with the baseline diagnosis showed excellent correlation 
with area under curve (AUC) of 0.90. 
 
 
Figure 5-1: ROC curve for Diabetes Predictor Score against WHO 1998 diagnostic 
criteria at baseline 
 A score of 25.80 was associated with sensitivity and specificity of 83 %. Positive and 
negative predictive values were 54 and 95% respectively. Using a higher cut-off at 
26.32 achieved similar sensitivity with better specificity at 87%. Positive and negative 
predictive values were 61 and 95% respectively. In comparison IEC criteria was 
associated with sensitivity of 57% and specificity of 94%. Positive and negative 
predictive values were 68 and 90% respectively. 
ROC curve for comparison with follow-up diagnosis also had excellent correlation 
with an AUC of 0.89.  
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Figure 5-2: ROC curve for Diabetes Predictor Score against WHO 1998 diagnostic 
criteria at follow-up 
 
A score of 25.80 was associated with a sensitivity of 86% and specificity of 85%. 
Positive and negative predictive values were 60 and 96% respectively. Using a 
higher cut-off at 26.32 achieved sensitivity of 81 and specificity of 89%. Positive and 
negative predictive values were 66 and 95% respectively. In comparison IEC criteria 
was associated with sensitivity of 67% and specificity of 95%. Positive and negative 
predictive values were 78 and 91% respectively. 
Discussion: 
Most guidelines recommend the OGTT as a gold standard investigation for assessing 
glycaemic status in patients with cardiovascular disease. However some recent 
studies have also compared a number of currently used diagnostic criteria for 
diabetes mellitus against W.H.O criteria ACS patients.  One such study looking at 
comparing admission HbA1c, FPG and admission plasma glucose (APG) with OGTT 
results has suggested poor correlation. Indeed the AUCs measured in this study 
were 0.72, 0.75 and 0.61 respectively for the three parameters (93). While this study 
provided some useful information it did not offer any solutions. More importantly 
the investigators only looked at data at hospital admission while I have also clearly 
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demonstrated the change in glycaemic status from baseline to follow-up at 3 months 
in the dysglycaemic group.  
On the other hand work done by Tahrani et al clearly demonstrated that using any 
of the parameters alone i.e. FPG or HbA1c is not enough. They initially performed 
univariate analysis with dichotomization of variables to obtain the optimum odds 
ratios (ORs) (200). For example, age was dichotomized to >65 years, BMI to 25 and 
waist circumference to 110cm as these gave improved significance over continuous 
variables and provided improved ORs over other clinically-meaningful cut-offs 
(200). Afterwards a stepwise logistic regression model was used showing only FPG 
(P<0.001, coefficient 1.23), HbA1c (P = 0.002, coefficient 1.59) and age> 65 years (P = 
0.049, coefficient 0.87) were significant variables (200).  The model was simplified by 
multiplying the coefficients by three and rounding to the nearest integers to generate 
the predictive model (PI) below: 
(3 * Age>65) + (4 * FPG) + (5 * HbA1c). (200) 
Although the performance of this model was better than quoted in any of the criteria 
used by de Mulder et al (93) it was still worse than the Diabetes Predictor Score 
designed by us. The sensitivity, specificity and AUC of this model were 76%, 77% 
and 0.77 respectively. The model did have an excellent negative predictive value at 
92.4%; however the positive predictive value was quite poor at 47% (200).By 
comparison our model gives us better sensitivity, specificity and AUC of 83%, 87% 
and 0.90 when compared to baseline diagnosis. Positive and negative predictive 
values were 68 and 90% respectively. When comparing it at 3 months the sensitivity, 
specificity and AUC were 81%, 89% and 0.89 respectively. Positive and negative 
predictive values were 66% and 95% respectively. Once again a major limiting factor 
of study done by Tahrani et al was the lack of complete glycaemic assessment at 3 
months as they only relied on repeat FPG at 3 months (200). 
To summarize employing a single glycaemic parameter alone does not seem to have 
a good correlation with WHO criteria. On the other hand as shown by our work as 
well as Tahrani et al a combination of age, fasting plasma glucose and HbA1c in a 
predictive model appeared to have the best correlation (200). The positive predictive 
values of these scores is relatively poor (although DPS does give>65% at baseline as 
well as 3 months compared to PI value of only 47%). This would suggest that using 
these models to exclude diabetes may be the most logical use. These parameters 
should also be relatively easy to obtain at an acute admission making them more 
practical rather than an OGTT which is associated with poor reproducibility as well 
as logistic constraints. 
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6.1 Summary: 
 
Despite the recognition of the importance of identification of undiagnosed pre-
existent diabetes mellitus in patients hospitalized with acute cardiac events, diabetes 
can often be overlooked or inappropriately labelled as an acute stress response.  In 
part, this may reflect a lack of consensus about the best screening modality to use in 
these patients or the complexity and costs associated with some methodology such 
as the OGTT (90, 97). Additionally limitations of the OGTT such as poor 
reproducibility, reflecting the high coefficient of variation of the 2 hour value, may 
limit its utility especially after acute medical stress.  Alternative simple screening 
methods such as the FPG and HbA1c would appear to be attractive methods in 
comparison.  However, HbA1c testing can be expensive, needs to be standardized 
and may not be universally available world-wide (97). HbA1c can be affected by 
racial origin and ethnicity (97, 99 and 100) and by anaemia and hemoglobinopathies. 
(97).  
The overall aim of my project was to explore the role of alternative screening 
methods which are more reproducible, easier to perform, less expensive and suitable 
for large scale screening in predicting long term glycaemic status in patients 
admitted to hospital with ACS. I therefore evaluated a screening algorithm based on 
FPG and HbA1c (101) and the HbA1c based IEC criteria in a cohort of patients 
admitted to hospital with ACS.  I was also able to design and evaluate a novel 
Diabetes Predictor Score which included basic parameters such as age, FPG and 
HbA1c.  
My study was carried out in two large inner city hospitals in United Kingdom and 
had a representation from wide age, sex and multi-ethnic groups. The participants 
were all admitted to hospital with ACS and underwent an initial OGTT within 7 
days of hospital admission which was followed up by glycaemic stratification at 3 
months 
Results demonstrated that on admission to hospital, 48% of participants had normal 
glucose tolerance (NGT) 32% impaired glycaemic status (IGS) and 20% met the 
criteria for T2DM based upon the 1998 WHO criteria.  These data illustrate the 
importance of screening for diabetes mellitus in patients admitted to hospital with 
ACS. In comparison with previous studies (81) the prevalence of diabetes was lower 
in our cohort.  This is likely to be related to our inclusion criteria and the nature of 
our population. 
At 3 months, 54% of participants had NGT while 25% IGS and 21% T2DM. While the 
prevalence of diabetes mellitus remained similar the percentage of participants in 
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the NGT group increased and IGS group decreased. I also noted an association of 
baseline glycaemic stratification with baseline urinary cortisol creatinine ratio 
suggesting stress hyperglycaemia may play a role in some of these glycaemic 
abnormalities detected at baseline.  However this relationship was lost at 3 months. 
There is also considerable debate about stress hyperglycaemia and whether it is 
cause or effect. 
Some studies have suggested the use of admission plasma glucose (APG) as a 
diagnostic tool for glycaemic status in comparison with WHO criteria (93). However 
as illustrated earlier the correlation between APG and WHO criteria is very poor 
(93). In my study only a third of the total number of participants had bloods checked 
for venous APG suggesting poor inpatient diabetes care. The number of participants 
in the category where APG was checked was so few that we could not reliably look 
at its association with final glycaemic outcomes. The rise in APG demonstrated in 
other studies during the acute admission can be looked as both a response due to 
stress as well as independent of stress and an isolated marker of both short term and 
long term dysglycaemia and poor cardiovascular outcomes as described in previous 
sections. I would therefore recommend that a combination of fasting plasma glucose 
and HbA1c should be the bare minimum in terms of glycaemic investigations in 
these patients.  
I would like to add here that the role of treating acute hyperglycaemia in the setting 
of acute myocardial infarction with therapies such as insulin has sparked some 
debate. In studies like DIGAMI for example it was suggested that treatment with 
insulin-glucose infusion followed by intensive subcutaneous insulin in diabetic 
patients with acute myocardial infarction improves long term survival. It was also 
demonstrated that the effect seen at one year continues for at least 3.5 years, with an 
absolute reduction in mortality of 11%. This means that one life was saved for nine 
treated patients. The effect was most apparent in patients who had not previously 
received insulin treatment and who were at a low cardiovascular risk (201). The 
investigators also looked at long term outcomes in these patients and suggested that 
mortality in these diabetic patients predicted by age, previous heart failure, and 
severity of the dysglycaemia at admission but not by conventional risk factors or sex. 
Intensive insulin treatment reduced long-term mortality despite high admission 
blood glucose and HbA1c (202). However results from DIGAMI 2 study were 
contrary to this.  DIGAMI 2 suggested treatment with insulin may be associated with 
an increased risk of non-fatal cardiac events, but not mortality while metformin 
appeared protective against mortality (203).  
There are two important messages from my work. Firstly it is important to detect 
and treat acute hyperglycaemia in both diabetic and non-diabetic patients admitted 
to hospital with acute myocardial infarction. I have confirmed in the previous 
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sections that even 1 mmol/l rise in blood glucose on admission in these patients can 
increase mortality by 4 times (116). This would suggest the importance of acute 
management of hyperglycaemia. DIGAMI and DIGAMI 2 studies also showed the 
importance of management of hyperglycaemia in the acute setting. Although in 
DIGAMI 2 insulin was associated with slight increase in non-fatal cardiovascular 
events while metformin was associated with improved cardiovascular and cancer 
outcomes (201-203).   
Secondly on a long term basis studies like UKPDS and DCCT have demonstrated the 
importance of strict glycaemic control in improving micro vascular and macro 
vascular complications of diabetes. There is still considerable debate about the macro 
vascular outcomes, however it is clear that the micro vascular complications of 
diabetes can be delayed if not prevented by achieving strict glycaemic control 
specially early after the diagnosis. This also shows the importance of our findings of 
detecting these patients and intervening early to prevent long-term complications. 
The application of either the WHO 1998 or the IEC diagnostic criteria gave a 
different prevalence of diabetes in our cohort (20% vs. 16% respectively at baseline 
or 21% vs.16% at 3 months). Fig 3-1 illustrates that at baseline we would miss almost 
half (43%) of the participants with DM diagnosed on W.H.O criteria by using IEC 
criteria. Similarly we would incorrectly identify 16% of participants in the IGS 
category as having DM on IEC criteria.  This clearly suggests by using the two 
different criteria we are identifying different cohort of patients with diabetes. Fig 3-3 
explores this relationship at 3 months. We would miss almost a third (33%) of the 
participants with DM diagnosed on W.H.O criteria by using IEC criteria. Similarly 
we would incorrectly identify 12% of participants with IGS and 2% of NGT as 
having DM based on IEC criteria. . Although the IEC criteria perform better at 3 
months we are still identifying different cohort of participants by using the two 
diagnostic criteria.  The reason for IEC criteria performing better at 3 months may be 
due to HbA1c reflecting longer term glycaemic status compared to OGTT.  
The difference in population detected with T2DM by using the two different criteria 
is clinically relevant as we are basing screening in a high risk population on these 
criteria. Another important point is the importance of recognizing patients with IGS. 
The American Diabetes Association have recommended using an HbA1c cut-off of 
5.7 to 6.4% to determine which patients may be at an increased risk of developing 
T2DM (118). Previous studies have suggested that in these groups of patients in the 
clinical setting of acute admissions with ACS 31% of them were diabetic according to 
WHO criteria (93). By contrast in my data a vast majority of participants 80(68%) had 
an HbA1c in this category and therefore this did not correlate very well with the 
group of participants with IGS according to WHO criteria. 9(11%) participants in this 
group had T2DM and 28(35%) had IGS with 43(54%) having NGT in comparison 
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with WHO criteria. Once again this poor correlation confirms our suspicion that the 
two criteria are identifying completely different cohorts. In addition we also need to 
look at the clinical and financial burden of managing the huge number of people in 
this category. As demonstrated in my study two thirds of the participants would 
have been classed as at risk of pre-diabetes if we had implemented ADA rather than 
WHO criteria 
These findings are particularly relevant as it is well known that patients with IGS 
have increased cardiovascular morbidity and mortality (76-80, 101). Patients with 
IGS are also known to progress to T2DM (89) with studies suggesting an incidence of 
around 57.2 per 1000 patient years (204). Other studies have suggested similar 
findings with incidence rates ranging from 35 to 58 per 1000 patient-years depending 
on ethnicity (205). IGT has also been known to be associated with increased 
cardiovascular mortality. The Whitehall study suggested a 2 fold increase in 
cardiovascular mortality in patients with abnormal OGTT results (2 hour PG>5.3 
mmol/l) vs. normal results (206). Studies have also examined the role of lifestyle or 
metformin (off label) therapy to reduce this progression (89). In this study 3 groups 
were compared i.e. placebo versus lifestyle intervention and metformin therapy. In 
the lifestyle intervention the incidence of diabetes was reduced by 58 percent and in 
the metformin group by 31 percent, as compared with placebo; suggesting life 
style intervention was significantly more effective than metformin. Putting these 
results in another way, in order to prevent a single case of diabetes during a time 
frame of three years, approximately 6.9 persons would have to be treated in 
the lifestyle-intervention program, and 13.9 would have to receive metformin (89) 
suggesting lifestyle intervention as being superior to metformin therapy. More 
recently a large meta-analysis was published looking at the effects of lifestyle 
intervention in reducing the incidence of T2DM and mortality in patients with IGT. 
Diabetes incidence in this meta-analysis varied from 3% to 46% in the intervention 
arm and 9.3% to 67.7% in the control cohort. These studies were carried out in 
various countries like India, Japan; Sweden etc. making it difficult to discern the 
effects of ethnicity (207).Mortality and morbidity was only studied in one of the 
included studies and did not suggest any statistically significant changes (208). The 
Da Qing study did show that group-based lifestyle interventions over 6 years could 
prevent or delay diabetes for up to 14 years (208). However the study was not 
powered enough to look at mortality and morbidity outcomes (208).The 
investigators of the large meta-analysis concluded that lifestyle intervention can 
have a beneficial effect on the incidence of T2DM in patients with IGT (207). 
However, rather disappointingly several studies found the effect of lifestyle 
intervention decreased after intervention was terminated 
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In my study the 3 participants who died all have abnormal glycaemic status with 
two of them having IGS at baseline. IEC criteria on its own would miss all these 
participants as the glycaemic stratification is only based on HbA1c. 
The screening algorithm developed locally appeared to have a good correlation with 
the WHO 1998 diagnostic criteria with sensitivity of over 85% at baseline as well as 3 
months. In comparison with IEC criteria it performed very well with sensitivity of 
100% as I did not miss any participants with diabetes mellitus. However I would 
have classified 3% incorrectly with diabetes mellitus. It would also lead to an over 
60% reduction in OGTTs compared to WHO criteria. This has potentially significant 
cost saving implications for National Health Service (N.H.S). The screening 
algorithm does have an advantage over IEC criteria with better sensitivity. In 
addition it also ensures we identify at least half (50%) of the participants with IGS. 
The IEC criteria in comparison will detect less than 20% of IGS subjects and would 
actually label them all as having T2DM. Earlier I mentioned that glycaemic 
stratification based on WHO 1998 diagnostic criteria changed from baseline to 3 
months. Closer examination reveals most of the patients in the NGT category 
remained unchanged (81%). While some of the participants changed in the T2DM 
category also changed (27%) most remained unchanged (73%) suggesting in these 
two categories we could rely on glycaemic classification at baseline as a predictor of 
long term glycaemic status. In comparison most of the participants in the IGS 
category did change (66%) with some of them becoming NGT (50%) and some also 
progressing to T2DM (16%). Previous studies had suggested we could rely on 
glycaemic diagnosis on baseline, however my data suggest in the IGS category a 
second OGTT is required at around 3 months to predict long term glycaemic 
diagnosis. 
The screening algorithm was originally designed to reduce the number of OGTTs 
rather than accurately defining glucose tolerance. Therefore I wanted to look at a 
different algorithm in our cohort which performed better in comparison with WHO 
criteria. I utilised a logistic regression model and used basic parameters such as age, 
sex, ethnicity, serum fructosamine, BMI, FPG and baseline HbA1c. Surprisingly I did 
not notice any significant association with BMI or fructosamine; however the other 
parameters such as age, FPG and HbA1c were all significantly associated as 
illustrated in table 5-2.  
Diabetes predictor score based on age, FPG and HbA1c appeared to perform better 
than IEC criteria if we use WHO diagnostic criteria as gold standard in this setting 
with both sensitivity and specificity of over 80%. ROC curves for DPS suggested 
excellent correlation with WHO diagnostic criteria at baseline and 3 months with 
AUC of 0.90 and 0.89 respectively. Sensitivity for DPS was much better than IEC 
criteria. It also appeared to show good concordance with the WHO criteria as it was 
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based on 3 parameters and not solely reliant on HbA1c. The DPS has excellent 
negative predictive values of over 90% at baseline as well as 3 months suggesting it 
can be used reliably as a rule out test. The positive predictive values were lower 
however suggesting we would identify some patients incorrectly with false positive 
results. We would postulate that DPS can be used in future as a test to exclude 
T2DM i.e. if DPS is negative T2DM can be excluded with a degree of certainty. 
However due to the poor positive predictive value, relying on it solely can lead to 
detection of a number of false positives. However based on our work as well as that 
of Tahrani (200) and de Mulder (93) it appears that our score has the best evidence as 
a test looking for concordance with WHO 1998 criteria. 
One of the novel features of my project was the exploration of pancreatic biomarkers 
in the participants. I noticed some interesting associations between the individual 
biomarkers and individual glycaemic measures.  I noted that at baseline mean c-
peptide, glucagon, intact pro-insulin and HOMA IR were higher in the diabetic 
group compared to normal and IGS groups. I also noted a trend for the leptin and 
the leptin adiponectin ratio to be higher in both diabetic and IGS groups compared 
to normal groups. However this relationship may have been driven by BMI. The 
only other biomarker which showed a clear association was HOMA IS which was 
found to be lower in the diabetic and IGS groups compared to normal cohort.  At 3 
months I noted that mean c-peptide, IL 1 RA, TIMP 2 and intact pro-insulin were 
higher in the diabetic group compared to NGT and IGS groups. The only other trend 
noticed was for HOMA IS to be lower among diabetics. This relationship may also 
be clinically relevant as there is considerable interest in developing commercial 
assays for these biomarkers. 
I was particularly interested in the concordance between the three glycaemic 
categories and the interchange between them at 3 months. I looked at them 
individually to discern any features which may help predict the group’s which were 
more likely to retain dysglycaemia. In the DM group I noted higher adiponectin, 
HOMA I.S and TIMP 1 levels among NGT and IGS compared to DM group at 3 
months. In the IGS group, TIMP 2 levels were lower in the NGT compared to IGS 
and DM groups at 3 months. There was also a trend towards higher FPG and systolic 
B.P in the IGS group compared to NGT and DM groups. In the NGT group, the only 
trend was diastolic B.P being higher in the normal compared to IGS groups. 
My study does have some limitations. The prevalence of diabetes was lower 
compared to previous studies which could impact some of our subsequent analysis. 
This is particularly relevant in some of the analysis about the three sub-groups and 
the interchanges between the groups at 3 months. Some of the numbers in these 
subgroups were extremely small. It is difficult to apply all our results to ethnic 
minority groups as 80% of our participants were white Caucasian. Another major 
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limitation appears to be related to gender as there is clearly a vast majority of males 
recruited in our study. However as illustrated in the previous sections my work is 
not unique in this regard. 
 Despite these limitations my study has provided interesting data about the different 
diagnostic modalities and their impact on prevalence of diabetes. I have 
demonstrated that the two main diagnostic methods currently used i.e. WHO 1998 
and IEC criteria appear to identify different populations with diabetes mellitus.  
6.2 Future Directions: 
 
I would have liked to follow-up these participants for a longer duration to look at 
their long term glycaemic status and its correlation with future cardiovascular events 
and cardiovascular mortality. I believe employing some of our algorithms and scores 
can help refine diagnosis of diabetes in this high risk category. My future aspiration 
would be to look at extending this work in other ethnic groups and also follow-up 
participants for a much longer duration. In addition this will also have potentially 
significant cost saving implications within N.H.S. In our own hospital the cost of an 
OGTT is around £64 suggesting clear reduction in acute hospital costs. 
 A novel aspect of my work was the use of novel biomarkers in predicting glycaemia 
in patients admitted with ACS. Indeed some of these biomarkers such as urinary c-
peptide are already in clinical use to aid diagnosis of diabetes mellitus. They may 
also help us determine long term glycaemic outcomes. One of our future aspirations 
is to look at relationship of these biomarkers with cardiovascular outcomes i.e. 
morbidity and mortality independent of the glycaemic status  
 To summarize different diagnostic criteria appear to suggest differing prevalence of 
diabetes mellitus. The performance of screening algorithms and predictor scores 
appears to be much better compared to IEC criteria on its own when using W.H.O 
1998 diagnostic criteria as gold standard. This is likely to be due to the inclusion of 
FPG in addition to HbA1c (and age in case of diabetes predictor score).I would also 
like to look at long term cardiovascular outcomes in participants with IGS and DM 
both with relevance to the novel biomarkers and on its own. 
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